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ABSTRACT 
 Sickle cell disease (SCD) is a group of inherited blood disorders characterized by 
recurrent pain. A distinctive obstacle to managing pain in this condition is the substantial 
heterogeneity of outcomes observed in children, including the rate, intensity, duration, 
and extent of disability from pain. Previous studies have largely examined this 
heterogeneity by focusing on either biomedical or psychosocial approaches to this 
condition rather than pursuing an integrated approach that is consistent with modern 
conceptualizations of pain. In addition, few studies have examining genetic heterogeneity 
in pediatric SCD, which remains one of the only strategies for establishing a preventative 
approach to pain in this condition. In contrast to these approaches, the present project 
describes an integrated biomedical and psychosocial approach to studying pain in 
pediatric SCD that consisted of two studies: (a) a study that examined an integrated, 
biopsychosocial model of pain in SCD and (b) a study that examined a novel genetic 
marker of pain variability in SCD. The results from these studies are provided along with 
discussion, clinical implications, and future directions for this work.  
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CHAPTER 1 
INTRODUCTION 
 Sickle cell disease (SCD) is a group of inherited blood disorders that affect 
approximately 1 in 400 to 500 newborns each year in the United States. The majority of 
these children are of African descent, though children from the Mediterranean, Middle 
East, Central America, and Central India are also affected (Gustafson, Bonner, Hardy, & 
Thompson, 2006). Painful vaso-occlusive episodes or ‘crises’ are considered the hallmark 
symptom of SCD. These episodes occur when abnormal red blood cells polymerize (i.e., 
change structure) and occlude areas of the microcirculation, resulting in reduced blood 
flow, tissue damage, and a painful inflammatory response.  
Pain episodes typically begin in childhood and can occur as early as the first year 
of life (Gill, et al., 1995); thus, pain is a salient issue for children with SCD. A distinct 
obstacle to effective management of pain in SCD is the substantial heterogeneity 
observed in children, including the rate, intensity, duration, and extent of disability from 
pain. Modern theoretical models suggest that this heterogeneity may be explained by a 
range of factors, including genetic and biological vulnerability and well as psychological 
and social processes (Embury, 2004); however, previous research has predominantly 
focused on either biomedical or psychosocial models of pain with little interdisciplinary 
integration of theory and methodology. Additionally, few studies have focused on 
identifying biomarkers of risk for pain, such as genetic markers, which may provide a 
method for identifying children at risk for pain and preventing adverse outcomes.   
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In contrast to these approaches, the current project describes an interdisciplinary 
approach to studying pain in children with SCD that was undertaken through two studies:  
(a) a study that examined an integrated, biopsychosocial model of pain in SCD and (b) a 
study that examined a novel genetic marker of pain variability in SCD. The current 
project focused specifically on children for two primary reasons. First, a focus on 
children allowed for a discussion of prevention and early intervention strategies. Second, 
research specific to children is especially needed given the unique circumstances of 
childhood, including the experience of a disease in the context of rapid developmental 
changes and the influence of important social environments, such as caregivers, on how 
children respond to pain.  
In order to provide a detailed background for the project, the dissertation 
document begins with a review of research on pain in pediatric SCD, including the 
clinical significance of pain, extent of pain heterogeneity, and previous theoretical and 
methodological approaches and findings. The dissertation follows with details of the two 
studies, including research aims and hypotheses, methods, and results. The document 
concludes with a discussion of the results, clinical implications, and future research 
directions. In order to aid the reader with specific terminology, an appendix of key terms 
and definitions is provided in Table 1.1.  
1.1 Clinical Significance of Pain in Pediatric SCD 
In children with SCD, recurrent pain from vaso-occlusive episodes may exert an 
impact on virtually all aspects of quality of life. Pain episodes can occur as early as the 
first year of life and persist into adulthood (Gill, et al., 1995; Platt, et al., 1991). Pain 
episodes are the most frequent source of morbidity and health care utilization in patients, 
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with some children requiring emergency room care or hospitalization for severe episodes 
(Platt, et al., 1991).  The unpredictable and debilitating nature of pain in SCD exerts a 
significant toll on the lives of children and their families. In addition to frequent medical 
visits, recurrent and severe episodes may lead to frequent school absences, academic 
attainment problems, reduced opportunity for physical recreation and social activities, 
and feelings of depression and anxiety (Anie, 2005; Edwards, et al., 2005; Fuggle, Shand, 
Gill, & Davies, 1996). Recurrent pain can also result in changes to areas of the peripheral 
and central nervous system responsible for processing pain, placing children at risk for 
the development of chronic pain over time (Smith & Scherer, 2010). Given the range of 
potential physical and psychosocial consequences for children with SCD, the 
identification of predictors of pain and the development of optimal prevention and 
intervention strategies in pediatric SCD are clearly important.  
1.2 The Issue of Pain Heterogeneity 
A distinct obstacle to effective management of pain in SCD is the substantial 
heterogeneity of outcomes in children, including the rate, intensity, duration, and location 
of pain and the extent of disability from pain (Gil, et al., 1993; Gil, Williams, Thompson, 
& Kinney, 1991; Platt, et al., 1991). This section provides descriptions of pain in children 
with SCD to illustrate this variability.  
According to the largest prospective epidemiological study of newborns and 
adults with SCD up to 66 years of age, approximately 30-40% of patients rarely to never 
have pain, 50% have several episodes per year, and 20% have frequent episodes per year 
(Platt, et al., 1991; Schechter, 1999). According to daily diary studies, pain is frequently 
managed at home, with approximately 40% of children having one episode per month 
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and 12% having more than two episodes per month (Dampier, et al., 2004; Shapiro, et al., 
1995). In addition to the rate of pain in SCD, pain intensity, duration, and location also 
vary across patients. Many children experience low levels of pain that are managed at 
home without medication (Gil, et al., 2000). When medication and health care services 
are used, they tend to occur at high levels of pain, ranging from a six to seven on a ten-
point scale. The duration of pain episodes has ranged widely, with some studies reporting 
a range of one to six days and others reporting durations that have lasted over two weeks 
(Dampier, et al., 2004; Gil, et al., 2000; Jacob, et al., 2003). For location, most pain is 
reported in the legs, though pain in the arm, knee, abdomen, and back are also common 
(Graumlich, et al., 2001). Pain that leads to health care use tends to occur predominantly 
in the chest, abdomen, or lower back (Jacob, et al., 2003).  
Children with SCD may also experience a range of outcomes in response to pain. 
While some children cope relatively well with pain, children with recurrent and severe 
episodes and those with limited resources for managing pain may experience detrimental 
outcomes. As noted previously, functional consequences to pain can include activity 
disruption, school absences, anxiety and depression, and reduced physical and social 
recreation (Anie, 2005; Edwards, et al., 2005; Fuggle, et al., 1996; Gil, et al., 1991).  
1.3 Theoretical Models of Pain in Pediatric SCD 
The issue of pain heterogeneity in SCD is compounded by the myriad of factors 
that likely influence the pain experience. These include numerous biological systems, 
psychological factors, and social influences. Although theoretical models are not always 
explicitly noted in individual studies of pain in SCD, research can be broadly categorized 
into studies that focus on biomedical versus psychosocial factors. These models are 
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briefly described, along with common examples of each type of research in pediatric 
SCD.  
The biomedical model conceptualizes disease in terms of measurable biological 
variables that indicate the presence or absence of disease or disease severity (Engel, 
1977). With regard to pain, biomedical models have historically focused on the biological 
mechanisms of tissue damage that produce the experience of pain (Keefe & France, 1999; 
Melzack, 1996). The intent of this research is to identify potential routes for medical 
treatments that can prevent or repair tissue damage or that can alleviate pain (Keefe, 
Abernethy, & Campbell, 2005).  The application of the biomedical model to sickle cell 
pain can be observed in large-scale epidemiological studies that have examined 
biological predictors of pain heterogeneity, studies of genetic variability in SCD, and 
basic science research that attempts to define the correlates and mechanisms of sickle cell 
vaso-occlusion (Embury, 2004; Higgs & Wood, 2008; Platt, et al., 1991; Sebastiani, 
Ramoni, Nolan, Baldwin, & Steinberg, 2005; Steinberg, 2005). Medical management of 
SCD pain is directed towards providing pain relief and preventing serious consequences, 
such as organ damage, through the use of opiate medication, non-steroidal anti-
inflammatory medications (i.e., NSAIDS), and blood transfusion (AAP, 2002).  Novel 
biomarkers that are linked to risk for pain (e.g., genetic markers) may provide a method 
of early identification and prevention of severe pain episodes, in addition to new 
treatment targets for SCD pain (Higgs & Woods, 2008).  
Psychosocial models suggest that pain is best conceptualized by considering 
psychological and social variables, in addition to biological mechanisms. The goal of this 
research is to identify psychosocial factors that affect pain or adjustment to pain, 
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particularly those that may be modifiable by behavioral intervention. Psychological 
variables include thoughts, feelings, and behaviors related to the pain experience, while 
social variables include aspects of the social environment that influence the 
communication of pain or responses to pain.  Psychosocial approaches to pain frequently 
pull from the theoretical underpinnings of the biopsychosocial model (described below); 
however, biological variables are not commonly assessed or integrated with the findings 
of psychosocial variables in these studies (Burlew, Telfair, Colangelo, & Wright, 2000). 
The application of a psychosocial approach to SCD can be observed in studies of child 
and caregiver psychological variables and familial influences in relation to pain and 
functional outcomes (Gil, Abrams, Phillips, & Keefe, 1989; Kliewer & Lewis, 1995; 
Lutz, Barakat, Smith-Whitley, & Ohene-Frempong, 2004). Psychosocial treatments in 
pediatric SCD have focused on education about SCD and the implementation of behavior 
changes (e.g., new coping strategies for pain) in the child and family (Chen, Cole, & 
Kato, 2004).  
In contrast to these approaches, an integrated, biopsychosocial approach to pain 
incorporates biological and psychosocial variables as well as their interrelationships. This 
model proposes a dynamic view of pain, in which pain can be both the antecedent and 
consequence of biological, psychological, and social variables. This view of pain was 
derived from modern theories of pain, including aspects of gate control theory and social 
learning theory (Keefe & France, 1999). Gate control theory suggests that the experience 
of pain can be modulated at multiple levels of the central nervous system, including areas 
of the brain responsible for psychological constructs (e.g., attention and mood) (Melzack, 
1996). This theory predicts that psychological factors will moderate the pain experience. 
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Social learning theory suggests that children learn to communicate and respond to pain 
through the social environment, such as by modeling adults or by reacting to the 
responses of caregivers (Craig, 1975; Craig, Lilley, & Gilbert, 1996).  Few applications 
of integrated, biopsychosocial approaches exist; however, they have the potential to guide 
integrated biomedical and psychosocial approaches for pain in pediatric SCD. 
1.4 Previous Research Findings  
The following sections describe primary research findings from each theoretical 
approach of pain in SCD. While a detailed description of the methodology of these 
studies is beyond the scope of this proposal, additional information on methodology is 
provided in Table 1.2. Additionally, a summary of primary research findings is provided 
in Table 1.3. The sections below focus predominantly on established research that has 
been replicated in multiple studies with children. Research on adults is also presented if 
literature is absent in a particular area or in cases where studies included both children 
and adults with SCD. Seminal studies or newer, promising areas of research are also 
highlighted. 
 Biomedical Findings. Biological predictors of pain have been predominantly 
studied by large-scale epidemiological investigations through the Cooperative Study of 
Sickle Cell Disease (the CSSCD), a consortium of multiple sites that treat children and 
adults with SCD. Research on genetic modifiers of disease severity have increased in 
recent years, though only a handful of markers of pain in SCD exist to date. This section 
will briefly review the most common laboratory and genetic markers of pain in SCD. 
Where the term “pain rate” is used in this section, pain was assessed based on the rate of 
health care utilization for pain (e.g., number of emergency room visits, hospitalizations, 
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and health care contacts for pain) within a specified range of time (e.g., within the past 
year).  
Laboratory Markers. The most prominent laboratory predictors of pain in SCD 
include hematocrit/hemoglobin and fetal hemoglobin. Hematocrit is the ratio of red blood 
cells to total blood volume. Hematocrit is also a derivative of hemoglobin, which is the 
amount of iron-containing protein in red blood cells. Although higher hematocrit is 
associated with a lower incidence of anemia, higher hematocrit is associated with a 
higher pain rate and a shorter duration between pain episodes (Dampier, Ely, Brodecki, & 
O'Neal, 2002; Platt, et al., 1991).  Higher hematocrit levels may be an indicator of higher 
blood viscosity, a measure of resistance to blood flow, which is a contributing factor to 
vaso-occlusion (Platt, et al., 1991). Fetal hemoglobin is a form of hemoglobin expressed 
during the first six months of life. Persistently high levels of fetal hemoglobin are present 
in some children with SCD, exerting a protective effect on pain. Specifically, higher fetal 
hemoglobin levels are associated with a lower pain rate and longer duration between 
episodes (Dampier, et al., 2004). Fetal hemoglobin may exert this protective effect by 
inhibiting the polymerization of red blood cells. Fetal hemoglobin is almost exclusively 
measured in children with sickle cell anemia (versus other subtypes; see below) (Platt, et 
al., 1991). 
Several additional biological correlates of pain variability have also been 
identified; however, hematocrit/hemoglobin and fetal hemoglobin are most consistently 
included in studies and have been found to be better predictors of pain rate, above and 
beyond several other laboratory markers (Platt, et al., 1991). Additional factors 
commonly assessed in clinical studies include coagulation factors (e.g., platelets) and 
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immune cells involved in the inflammatory response to pain (e.g., white blood cells).  
Vaso-regulatory factors that modify the constriction and dilation of red blood cells are 
also strongly implicated (Embury, 2004).  (Genetic variability in a specific vaso-
regulatory system, the endothelin system, will be the focus of the Study Two of the 
dissertation, discussed in great detail later). 
Genetic Factors. As the result of the great phenotypic heterogeneity observed in 
patients, modern views of SCD suggest that it is a multifactorial disorder influenced by 
several genetic and environmental modifiers, including possible gene-gene and gene-
environment interactions and epigenetic factors that modify gene expression (Higgs & 
Wood, 2008). Genetic variability can be examined as broadly as the level of SCD 
subtypes and at the level of the individual. 
Sickle cell disease is comprised of several subtypes. The most common subtype is 
homozygous HbSS or sickle cell anemia, which is estimated to affect approximately 60% 
of those with SCD in the United States. Subtypes are distinguished by variations in 
hemoglobin. Additional forms of SCD include HbSC, comprised of hemoglobin S and C, 
and the HbSβ0  and HbSβ+  thalassemias, comprised of hemoglobin S and a mutant beta 
globin gene. HbSC is estimated to affect approximately 30% of those with SCD and the 
thalassemias together are estimated to affect approximately 10% of those with SCD in the 
United States (Hassell, 2010). Children with HbSβ0 have a beta globin gene that has been 
rendered inactive, while children with HbSβ+ have reduced levels of normal beta globin 
(Frennette & Atweh, 2007). Children with the HbSS and HbSβ0 subtypes tend to exhibit a 
more severe disease trajectory versus the HbSC and HbSβ+ subtypes, including a higher 
pain rate and longer duration of pain episodes (Dampier, et al., 2004; Platt, et al., 1991). 
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This finding may be explained by the “dosage” of the sickle cell trait and the tendency 
towards sickle cell polymerization in the HbSS and HbSβ0 subtypes. Although variability 
exists at the level of SCD subtypes, there is much greater heterogeneity observed within 
subtypes, suggesting that additional biological and environmental factors are involved 
(Embury, 2004; Platt, et al., 1991).  
 The presence or absence of alpha thalassemia trait represents another aspect of 
genetic variability. Alpha thalassemia trait is present when one or more of the alpha 
globin genes composing hemoglobin have a genetic mutation (Platt, et al., 1991). The 
presence of this trait has been associated with a higher pain rate; however, the trait has 
ameliorative effects on other aspects of disease severity, such as anemia (Gill, et al., 
1995). The effects of alpha thalassemia trait on pain rate have been explained by higher 
hematocrit levels observed in these patients, previously noted to increase blood viscosity 
and to contribute to vaso-occlusion (Embury, 2004; Platt, et al., 1991). 
 Additional studies of genetic variability through the CSSCD have examined 
associations between single nucleotide polymorphisms (SNPs), which are genetic 
mutations at the level of a single gene, and pain rate. A few promising studies have found 
that genetic variation underlying fetal hemoglobin levels is associated with pain rate.  In 
Lettre, et al. (2008), authors found that five SNPs accounted for over 20% of the variance 
in fetal hemoglobin levels (see Table 1.3 for specific SNPs). Their statistical model also 
demonstrated that the pain rate of patients with SCD could be predicted by genotype 
(Higgs & Wood, 2008; Uda, et al., 2008). Although this research appears promising for 
developing markers of risk for pain, few other examples of studies examining genetic risk 
for pain in SCD exist.   
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Brief Summary of Findings. Biomedical approaches to SCD have identified 
consistent predictors of pain rate; however, there is still a large amount of unexplained 
variability in pain that is not accounted for by existing biomarkers. For example, 
hematocrit and fetal hemoglobin collectively account for about five percent of the 
variance in pain rate (Platt, et al., 1991; Lettre, et al., 2008). Additionally, little is known 
about biomarkers of pain features aside from rate (e.g., intensity, duration), and pain rate 
has been almost exclusively defined by using health care utilization as a proxy.  Rather 
than being a pure measure of pain rate, health care utilization measures can also capture 
aspects of the health care environment and experience (e.g., relationships with health care 
personnel) (Smith, et al., 2005). Additionally, this method does not capture pain that is 
managed at home without health care contact (Shapiro, et al., 2005).  
Establishing laboratory and genetic markers of pain variability appears to be a 
promising approach to identifying children at risk for severe pain, and it remains the only 
approach with the potential to lead to preventative approaches to pain in SCD (Frennette 
& Atweh, 2007). Additionally, identifying novel genetic markers may provide new routes 
for treatment (Higgs & Woods, 2008). However, existing markers cannot identify 
children at risk for pain reliably, and current treatment approaches depend on children 
demonstrating morbidity (e.g., severe pain episodes) prior to treatment. Additional 
research is clearly needed in this area, particularly in terms of understanding genetic 
variability. Study Two of this proposal will target this particular limitation of research by 
studying a novel genetic marker of pain variability, discussed in greater detail later. 
12 
 Psychosocial Findings. Psychosocial approaches to SCD pain have established 
several important correlates of pain variability. These include both child- (e.g., child 
coping) and family-level factors (e.g., caregiver coping).  
Child Factors. At the child level, several studies have established the importance 
of coping strategies in relation to pain variability. Using the stress and coping framework 
of Lazarus and Folkman (1984), coping with regard to pain can be defined as the 
thoughts or behaviors children use to manage pain or pain-related stressors. In SCD, two 
primary types of coping constructs have been studied: coping attempts and negative 
thinking. Coping attempts are active behaviors or ways of thinking about pain that a child 
uses to reduce pain, such as distraction, calming statements, or increasing activity level. 
Negative thinking is focused on rumination or magnification of pain, such as thinking the 
pain will never end, that no one can help with the pain, or thinking about the negative 
impact of pain on one’s life (Gil, et al., 1991; Rosenstiel & Keefe, 1983).  
Through the use of multiple methods, including correlational, experimental, and 
intervention designs, several studies have established that active coping attempts tend to 
be related to better pain outcomes versus negative thinking. Specifically, coping attempts 
are related to lower pain sensitivity, lower health care utilization, and higher activity 
levels. In contrast, negative thinking is associated with higher pain sensitivity, higher 
health care utilization, lower activity levels, higher ratings of distress, and poorer 
psychological adjustment (Anie & Green, 2012; Gil, et al., 1989; Gil, et al., 1991; 
Thompson, Gil, Burbach, Keith, & Kinney, 1993). Intervention research has 
demonstrated that active coping strategies can be learned by children with SCD and can 
modify pain sensitivity. Gil and colleagues (1997, 2001) demonstrated that a brief 
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training in active coping strategies, including deep breathing, relaxation, and guided 
imagery, reduced the use of negative thinking and lowered pain sensitivity during a 
standardized laboratory task in children who practiced the coping strategies. Similar 
findings have been demonstrated in adults with SCD (Gil, et al., 1996, 2000). 
 An additional psychological factor that may be important for pain in SCD is 
mood. Mood can be defined as an emotional state that varies on two dimensions: positive 
and negative.  Positive mood is the degree to which individuals feel joyful and energetic. 
In contrast, negative mood is the degree to which individuals feel sad, nervous, angry, or 
distressed (Laurent, et al., 1999; Watson, Clark, & Tellegen, 1988). Gil and colleagues 
(2003) examined mood in 37 adolescents with SCD using a daily diary approach. Diaries 
were collected for up to six months. Mood was assessed by asking adolescents the degree 
to which they felt different positive and negative emotions. Adolescents reported on pain 
intensity, duration, health care utilization, distress, and activity levels as primary 
outcomes. The authors found that negative mood was related to greater pain intensity, 
greater health care utilization, and lower activity levels and that positive mood was 
related to lower pain intensity, lower health care utilization, and higher activity levels. 
These authors have also demonstrated similar findings with adults (Gil, et al., 2004). In 
addition to these findings, mood is widely viewed to be an important psychological 
correlate of pain in both SCD and other pain conditions (Keefe, et al., 2005; Porter, Gil, 
Carson, Anthony, & Ready, 2000; Porter, et al., 1998; Serjeant, et al., 1994). 
Social Factors. Although social factors may not directly impact the pain 
experience, they are relevant for two primary reasons: (a) social factors can influence 
important psychological factors that directly impact pain (e.g., the development of coping 
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skills) and are therefore integral to interventions for pain and (b) social factors can 
influence the treatment of pain in children through caregiver and provider decision-
making (Kenneth, Lilley, & Gilbert, 1996). For children with SCD, the most widely 
studied social factor is the family environment.  
Several studies in SCD have focused on the contribution of family-level factors to 
how children respond to pain, with the strongest findings supporting the influence of 
caregiver coping and family functioning on children’s responses to pain. Children’s 
coping strategies tend to coincide with caregiver coping strategies for pain in SCD, 
suggesting that social modeling may be important for understanding the development and 
maintenance of coping strategies in children (Gil, et al., 1991; Kliewer & Lewis, 1995; 
Lutz, et al., 2004). Family functioning, defined by how a family cooperates together as a 
unit, has been consistently related to child and caregiver coping; however, the exact 
manner in which family processes influence child and caregiver coping is likely to be 
complex (Kliewer & Lewis, 1995; Lutz, et al., 2004). For example, greater family 
cohesion, a component of family functioning, has predicted active coping in children and 
caregivers in some studies and maladaptive coping in others (Brown, et al., 1993); thus, 
qualities of family functioning, such as the extent to which cohesion promotes active 
coping in children versus dependence on caregivers, may be important (Kliewer & Lewis, 
1995). 
Additional family-level variables that may be relevant include caregiver 
psychological functioning and caregiver-child communication around pain; however, 
research in this area is sparse and requires replication. Caregiver psychological 
functioning has been linked to child adjustment and rates of health care utilization in 
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SCD (Logan, Radcliffe, & Smith-Whitley, 2002; Thompson, et al., 1993). Child 
adjustment, which can include aspects of mood, may be an important correlate of adverse 
pain outcomes (Edwards, et al., 2005); thus, the extent to which caregivers influence 
child adjustment may be relevant for understanding pain in SCD. Although research is 
sparse for understanding caregiver characteristics that impact pain, this research may 
suggest opportunities for family-level intervention for pain.  
Brief Summary of Findings. Research has demonstrated that psychosocial factors 
are integral to understanding pain variability in children with SCD. The most consistent 
evidence exists in the area of coping, with child coping consistently associated with pain 
outcomes. Additionally, specific family-level factors, such as caregiver coping and 
family functioning, appear to be relevant for understanding the development and use of 
coping strategies in children. Psychosocial studies have also focused on a range of pain 
outcomes (e.g., pain features and functional outcomes). Although these studies tend to 
use small to moderate sample sizes, the effect sizes for child psychological variables, in 
particular, have been moderate to large in size, ranging from R2 of .06 to .17. 
Nonetheless, this approach is limited by the absence of research on how family-level 
factors impact pain outcomes, in addition to their influence on child coping and 
adjustment.  
 Integrated Biopsychosocial Findings. Modern theoretical models of pain and 
chronic illness support an integrated approach to research that combines biomedical and 
psychosocial approaches (Engel, 1977; Keefe & France, 1999). There are currently no 
examples of this type of research focused on pain in children with SCD; however, two 
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examples of integrated research in SCD provide useful templates: the PiSCES project and 
biopsychosocial studies of adjustment in pediatric SCD. 
The PiSCES Project. The stated aim of the Pain in Sickle Cell Epidemiology 
Study (PiSCES) project is to “validate a biopsychosocial model of SCD pain, pain 
response, and health care utilization in a large, multisite adult cohort” (Smith, et al., 
2005). As this statement illustrates, the PiSCES project is designed to examine an 
integrated model of pain. The study is a large, multisite endeavor conducted as part of the 
CSSCD.  Common biomarkers of pain variability (e.g., hematocrit), psychological factors 
(e.g., coping), and social factors (e.g., social support, health care issues) are examined. 
Pain outcomes, including rate, intensity, duration, location, and health care utilization, 
and medication usage are assessed via daily diaries. These characteristics demonstrate a 
true integration of biopsychosocial theory and methodology. Although several studies 
have been published from this project, the examination of interrelationships among 
biological and psychosocial predictors has not been published. Nonetheless, the methods 
of this study provide a useful template for how integrated research across multiple 
disciplines can be accomplished in SCD. 
Biopsychosocial Models of Adjustment. Another potentially useful line of 
integrated research in SCD comes from studies that have applied a biopsychosocial 
model of adjustment to SCD in children (Burlew, et al., 2000; Thompson, et al., 1993). 
The strength of this research is that it has focused on integration of biopsychosocial 
factors in children; thus, these studies considered issues that are pertinent to a pediatric 
population (e.g., use of measures and constructs appropriate for children, examination of 
family-level factors). These studies have also focused on the assessment of moderators 
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and mediators of psychological adjustment, an approach that may be used to examine 
pain outcomes in SCD (Burlew, et al., 2000; Lutz, et al., 2004).  Biopsychosocial studies 
of adjustment have generally focused on how the impact of disease parameters (e.g., 
biomarkers and clinical events) on child and caregiver adjustment (e.g., ratings of 
depression) is moderated or mediated by psychosocial factors (e.g., child and caregiver 
coping).  This line of research has been successful in demonstrating the utility of using a 
biopsychosocial model in predicting variability in adjustment outcomes. For example, 
this research has consistently demonstrated that psychosocial variables may play a larger 
role in predicting adjustment in SCD than biological factors, a finding that is important to 
consider for intervention planning (Barakat, Schwartz, Simon, & Radcliffe, 2007; 
Burlew, et al., 2000; Lutz, et al., 2004).  
Brief Summary of Findings. Currently, no published findings exist on the 
relative contributions of biological and psychosocial factors to pain in SCD, and an 
integrated model has yet to be used in children with SCD to predict pain. Examples of 
integrated approaches exist for adults with SCD and for children to predict adjustment 
outcomes; however, there are several unanswered questions with regard to how 
biopsychosocial factors impact pain in SCD.  
First, we do not know the relative contributions (i.e., relative effect sizes) of 
biomedical versus psychosocial variables on pain variability, which is important when 
considering the allocation of resources to treat pain. Second, we do not know the 
contributions of biomedical and psychosocial to specific pain outcomes, which may be 
useful for tailoring treatment approaches to patients. For example, children may vary in 
the extent to which certain features impact quality of life (e.g., pain intensity versus 
18 
frequency). Third, no studies have examined how biopsychosocial variables interact to 
produce pain. For example, psychological factors may moderate the impact of biology on 
pain, as predicted by the gate control theory, or these variables may act independently of 
one another. The focus of Study One of this proposal is to examine an integrated model 
of pain in children with SCD, in order to address these limitations. 
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Table 1.1. 
Glossary of Terms and Definitions 
Term Commonly Used Definitions 
Biomedical Variables  
    Hematocrit The ratio of red blood cells to total blood volume  
    Hemoglobin The iron-containing protein of red blood cells that transports 
oxygen from the lungs to the body  
    Fetal Hemoglobin Form of hemoglobin expressed during the first six months of life; 
persistently high levels beyond the first six months of life are 
found in some individuals  
    Single nucleotide polymorphism   A mutation of a single nucleotide in a gene; also called a SNP 
Psychological Variables  
    Coping Constantly changing efforts to combat internal or external events 
that are appraised by an individual as challenging  
        Child Coping  
            Coping Attempts Engaging in active thinking or behavioral strategies to reduce pain  
            Negative Thinking Engaging in thoughts about pain that are characterized by 
rumination or magnification of pain  
        Caregiver Coping  
            Active Coping Engaging in active thinking or behavioral strategies to reduce pain 
(similar to child coping attempts) 
            Passive Coping Engaging in passive strategies, such as rumination about pain 
(similar to child negative thinking) 
    Mood A state of positive (e.g., happy, excited) or negative (e.g., sad, 
fearful) affect  
Social Variables  
    Social modeling Display of behaviors to children that are then attended to, learned, 
and exhibited by children 
    Family functioning The degree to which a family generally functions together as a 
unit 
Pain Outcomes  
    Pain rate/frequency The number of pain episodes occurring in a specified period of 
time 
    Pain intensity The subjective amount of pain experienced by a patient; can be a 
particular episode or average pain intensity 
    Pain duration The length of time that a pain episode occurs; can be a particular 
episode or average pain duration 
    Pain location The part or parts of the body in which the patient interprets the 
pain as occurring  
    Health care utilization The degree to which a patient uses health care services for pain; in 
SCD, services may range from routine visits or calls to emergency 
room care or hospitalization 
    Functional outcomes The degree to which pain interferes with a patient’s emotional, 
social, and occupational well-being 
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Table 1.2. 
Biomedical, Psychosocial, and Integrated Approaches to Studying Pain in Sickle Cell Disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. This table provides descriptive information on biomedical, psychosocial, and integrated approaches to studying pain in sickle cell disease (SCD) based on 
common characteristics of existing studies. CSSCD = Cooperative Study of Sickle Cell Disease 
Theoretical Model Methods Key Variables Key Outcomes Strengths Limitations 
Biomedical 
Model 
Large sample size, 
multi-site CSSCD 
Biomarkers: 
Hematocrit 
Fetal hemoglobin 
Genetic variability 
(SCD subtypes, alpha 
thalassemia, variation 
in fetal hemoglobin) 
Pain rate (often 
assessed by health 
care utilization) 
 
 
Guide for medical 
management, 
including prevention 
and intervention 
 
Generalizability of 
findings is high 
Ignores patient- and 
social-level factors 
 
Pain features aside 
from rate not widely 
studied 
Psychosocial 
Model 
Small-to-moderate, 
single site samples 
 
Systems approach 
(i.e., patient- and 
social-level factors) 
 
Multi-modal 
assessment of pain 
Patient-level: 
Child coping 
Child mood 
 
Social-level: 
Parental coping 
Parental psychological 
functioning 
Family functioning 
 
Multiple pain 
features: 
Rate 
Intensity 
Duration 
Location 
 
Health care utilization 
 
Functional outcomes 
 
Guide for behavioral 
interventions 
 
Incorporates patient- 
and social-level 
factors 
 
Multimodal 
assessment of pain 
 
 
Generalizability of 
findings only to one 
site 
 
No guide for 
prevention of pain 
 
No integration of 
biomedical and 
psychosocial variables 
Biopsychosocial/ 
Integrated Model 
Large sample size, 
multisite for CSSCD 
(could be variable) 
 
Interdisciplinary 
collaboration 
 
Systems approach 
 
Multi-modal 
assessment of pain 
Biomarkers 
 
Patient- and social-
level variables 
 
Interrelationships 
among variables: 
establishing key 
mediators and 
moderators of pain 
Multiple pain features 
and outcomes 
 
Psychological 
adjustment 
Guide for integrated 
approach to pain 
management 
 
Incorporates multiple 
levels of analysis and 
tests modern models 
of pain 
 
Resource sharing and 
collaboration 
Different research 
approaches (e.g., 
measures, statistical 
methods) must be 
integrated 
 
No research focusing 
on pain in children 
with SCD 
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Table 1.3. 
Summary of Biopsychosocial Variables in Relation to Pain in Pediatric Sickle Cell 
Disease 
 
 
 
Biomedical Variables Relationship to Pain Outcomes References 
Hematocrit (Hct) ↑Hct ↑pain rate (health care 
utilization)  
 
Dampier, et al., 2004; Platt, et al., 
1991 
Fetal hemoglobin 
(HgF) 
↑HgF ↓pain rate (health care 
utilization) 
 
Dampier, et al., 2004; Platt, et al., 
1991 
SCD Subtype  HbSS, HbSβo > HbSC, HbSβ+  for 
pain rate and duration  
 
Dampier, et al., 2004; Gil, et al., 
1991; Platt, et al., 1991 
Alpha thalassemia trait  Presence of trait ↑pain rate (health 
care utilization) 
 
Gill, et al., 1995; Platt, et al., 1991 
Single nucleotide 
polymorphisms (SNPs): 
BCL11A 
    rs4671393 
HBS1L-MYB 
    rs28384513 
    rs9399137  
    rs4895441  
β-globin gene cluster 
XmnI            
    rs7482144 
Collectively, all five SNPs 
significantly predicted ↓pain rate 
(health care utilization) in Lettre, et 
al., 2008 
 
No statistically significant effect 
for individual SNPs 
 
 
Lettre, et al., 2008; Uda, et al., 
2008 
Psychological 
Variables 
Relationship to Pain Outcomes References 
Child coping ↑ Coping attempts ↓pain 
sensitivity, ↓health care utilization, 
↑activity levels 
 
↑ Negative thinking ↑pain 
sensitivity, ↑health care utilization, 
↓activity levels 
 
Anie, et al., 2002; Gil, et al., 1989, 
1991, 1993, 1997, 2001 
Adults: Gil, et al., 1996, 2000 
Mood Negative mood ↑pain intensity, 
↓activity levels 
 
↑ Positive mood ↓pain intensity, 
↑activity levels, ↑school attendance 
Gil, et al., 2003 
Adults: Gil, et al., 2004 
Social Variables Relationship to Child Outcomes References 
Parental coping Child coping for pain mirrors 
caregiver coping  
 
Gil, et al., 1991; Kliewer & Lewis, 
1995; Lutz, et al., 2004 
Family functioning Complex, depends on extent to 
which family promotes adaptive 
coping 
Brown, et al., 1993; Kliewer & 
Lewis, 1995; Lutz, et al., 2004 
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CHAPTER 2 
THE CURRENT PROJECT 
In reviewing biomedical and psychosocial approaches to SCD pain, it is clear that 
both approaches have contributed to the current understanding of pain and treatment 
approaches for pain in SCD; however, there are few examples of studies that integrate 
biomedical and psychosocial approaches to pain as well as minimal research on genetic 
markers of pain heterogeneity. The current project aimed to build from previous research 
through two studies described below: (a) a study that examined an integrated, 
biopsychosocial model of pain in pediatric SCD and (b) a study that examined a novel 
genetic marker of pain in SCD. 
2.1 Study One: Examine an Integrated, Biopsychosocial Model of Pain in Pediatric 
SCD 
Modern theoretical models of pain, including gate control theory and the 
biopsychosocial model of pain, suggest that a combination of biological, psychological, 
and social factors contribute to pain. Specifically, these models suggest that 
psychological factors, such as coping and mood, modulate the relationships between 
biological factors and pain (Melzack, 1999). The biopsychosocial model also proposes 
that individual reactions to pain are often established and reinforced by the social 
environment (Keefe & France, 1999). Previous cross-sectional, experimental, and daily 
diary studies by Gil and colleagues (1989, 1991, 1997, 2001, 2003) have indicated that 
psychological factors, such as coping and mood, may play a central role in understanding
 23 
 
pain variability, including pain sensitivity, pain intensity, and health care utilization for 
pain. Additional research on the social environment of children with SCD indicates that 
caregiver and familial factors, such as caregiver coping and family functioning, may 
influence children’s development of strategies to manage pain (Kliewer & Lewis, 1995; 
Lutz, et al., 2004).  
Despite these findings, there is little information on how these variables 
collectively influence pain. The following aims and hypotheses focused on developing an 
integrated, biopsychosocial model of pain in pediatric SCD.  
 Study One: Aims and Hypotheses. 
  Aim I: Compare the effect sizes of biological and psychological factors in 
relation to multiple pain outcomes in pediatric SCD. For Aim I, effect sizes were 
examined to better understand the role of specific biological (sickle cell subtype; 
hematocrit and fetal hemoglobin) and psychological (child coping and mood) factors 
previously demonstrated to be predictive of pain in SCD. This information may be useful 
for understanding the relative contributions of biomedical and psychological factors to 
multiple pain features for the purposes of allocating resources to treat pain and to tailor 
treatment approaches to specific pain features. To assess pain, multiple pain outcomes 
were assessed, including pain rate, intensity, duration, and health care utilization. For 
Aim 1, the following hypotheses were made: 
Hypothesis 1: Biological variables (sickle cell subtype; fetal hemoglobin and 
hematocrit) will be associated with pain rate and health care utilization for pain, with an 
approximate, cumulative R2 of .05 or higher. This effect size estimate was derived from 
two large, epidemiological investigations that consistently supported an R2 of .05 for 
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these biological variables when pain rate was assessed based on health care utilization 
(Lettre, et al., 2008; Platt, et al., 1991). Hypothesis 2: Child psychological variables 
(child coping and mood) will be associated with pain intensity and health care utilization 
for pain, with approximate R2 values of .12 for pain intensity and .08 for health care 
utilization, respectively. These effect size estimates were based on previous research 
estimating the effects of coping and mood on pain outcomes in SCD, with effect sizes 
ranging from .06 to .17 for pain intensity and .06 to .10 for health care utilization (Gil, et 
al., 1989; Gil, Abrams, Phillips, & Williams, 1992; Gil, et al., 2003; Gil, et al., 1991). 
These estimates were averaged to develop specific hypotheses. No hypotheses were 
provided for pain duration due to an absence of published effect sizes; analyses with pain 
duration were considered exploratory.  
Aim II: Explore interrelationships among biological and psychological factors. 
Modern theoretical models of pain suggest that a combination of biological, 
psychological, and social factors contribute to pain. Specifically, theoretical models of 
pain suggest that psychological factors are involved in pain perception and may moderate 
the impact of biological factors on pain (Keefe & France, 1999; Melzack, 1999). Few 
studies have examined how biological and psychological factors work together to impact 
pain in pediatric SCD, which was the goal of Aim II. Two competing hypotheses about 
the relationships between biological and psychological factors and pain were made:  
Hypothesis 3: Biological and psychological factors will operate independently of 
each other, such that child coping and mood have an additive relationship with biological 
factors (sickle cell subtype; fetal hemoglobin and hematocrit) in predicting pain 
outcomes. Hypothesis 4: Consistent with modern theoretical models of pain (Keefe & 
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France, 1999; Melzack, 1999), child coping and mood will moderate the relationship 
between biological factors and pain outcomes. Specifically, greater use of maladaptive 
coping strategies or negative mood will have a synergistic effect with biological risk; 
greater use of adaptive coping strategies or positive mood will buffer the effects of 
biological risk. Given the possibility of small effect sizes for biological predictors, these 
analyses were considered exploratory, with a focus on both effect sizes and statistical 
significance.  
Aim III: Examine relationships between child psychological variables, 
caregiver psychological variables, family functioning, and pain outcomes. This aim 
focused on the relationships between child and caregiver psychological variables and 
family functioning as well as their relationship to pain outcomes. Results from this aim 
were anticipated to provide information that could inform mediation analyses to 
understand relationships between caregiver and family factors and child pain outcomes in 
SCD as well as potential mechanisms for these effects (e.g., child coping or mood). The 
following hypotheses were made: 
Hypothesis 5: Child coping and mood will mirror caregiver coping and mood 
(e.g., higher adaptive coping in caregivers will be associated with higher adaptive coping 
in children). Hypothesis 6: Better ratings of family functioning will be correlated with 
higher coping attempts and lower ratings of negative thinking in children. Hypothesis 7: 
Caregiver coping, mood, and family functioning will be correlated with health care 
utilization. Specifically, higher active coping, higher positive mood, and higher family 
functioning will be associated with lower health care utilization, while higher passive 
coping, higher negative mood, and lower family functioning will be associated with 
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higher health care utilization. Exploratory analyses were conducted for pain rate, 
intensity, and duration. 
2.2 Study Two: Examine a Novel Genetic Marker of Pain in Pediatric SCD 
The great heterogeneity of pain observed in SCD has led to modern views of SCD 
as a multifactorial disorder influenced by several underlying biological and 
environmental factors (Higgs & Wood, 2008).  The identification of biomarkers of pain 
risk, including genetic markers, has been proposed as a promising method for identifying 
children early in life and preventing adverse consequences from severe pain (Lettre, et 
al., 2008). Additionally, novel genetic markers may suggest new routes for treatment of 
pain (Higgs & Woods, 2008). 
Previous epidemiological studies have found that variations in hematocrit and 
fetal hemoglobin levels and genetic variants hypothesized to be involved in the regulation 
of fetal hemoglobin are predictive of pain rate in SCD. Although these markers have 
explained statistically significant variability in pain rate, there is substantial variability in 
pain that remains unexplained. Additionally, aside from genetic markers of fetal 
hemoglobin, there are likely to be several other genetic and epigenetic factors that are 
predictive of pain severity (Higgs & Wood, 2008; Lettre, et al., 2008; Platt, et al., 1991).  
Of the candidate genes that have been described in relation to pain, genes 
involved in vaso-regulatory systems have been strongly implicated. Vaso-regulatory 
factors are thought to contribute to both the initiation and duration of pain due to their 
influence on blood velocity and the transit time of sickled cells in the microcirculation. 
Levels of endothelin-1 (ET-1), a potent vaso-active peptide, increase in response to 
conditions of low oxygen and the sickling of cells in the endothelium that occur during 
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pain episodes. Due to its vaso-constrictive properties, ET-1 may delay the transit time of 
sickled cells out of the endothelium, thereby contributing to vaso-occlusion (Hebbel, 
Osarogiagbon, & Kaul, 2004). The biological actions of ET-1 are mediated by two 
receptors (ET-A, ET-B). The ET-A receptor is expressed on vascular smooth muscle cells 
and mediates vasoconstriction. In contrast, the ET-B receptor is expressed on endothelial 
cells and mediates vasodilation (Khodorova, Montmayeur, & Strichartz, 2009). Over the 
past several years, single nucleotide polymorphisms (SNPs) in coding regions for these 
receptors have been associated with several aspects of vessel regulation, including 
alterations in cardiovascular function and exercise-induced arterial adaptation (Dong, 
Wang, Zhu, Treiber, & Snieder, 2004; Iemitsu, et al., 2006).  
A preliminary study of two specific SNPs in the endothelin system was 
undertaken to assist in the development of Study Two and to inform specific hypotheses. 
The following is a description of the findings from the preliminary study. 
 Preliminary Study of Endothelin Receptor SNPs and Pain Rate. A 
preliminary study of two SNPs in the ET-A and ET-B receptors (rs5333 and rs5351, 
respectively) was conducted with 20 children with SCD (all subtypes) ages 2 to 17 years 
and their families. The data was collected as part of a larger study of 61 children with 
SCD that examined plasma endothelin levels during procedural pain. Participants were 
recruited at the Center for Children’s Cancer and Blood Disorders (the primary 
recruitment site for the current project). Genotyping for the ET-A and ET-B SNPs was an 
exploratory component of this study and samples were not available from all participants. 
Genotyping was conducted on 12 of 20 plasma samples for the ET-A SNP and 14 of 20 
samples for the ET-B SNP (not all plasma samples were successfully amplified). The 
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breakdown of SCD subtypes within each SNP was as follows: ET-A A/A (HbSS n = 3, 
HbSβ+ n = 1), A/G (HbSS n = 4, HbSC n = 1), and G/G (HbSS n = 1, HbSβ+ n = 1); ET-
B A/A (HbSS n = 1, HbSβ+ n = 1), A/G (HbSS n = 1, HbSC n = 1, HbSβ+ n = 2), and 
G/G (HbSS n = 8). 
Figure 2.1 shows the genotypes for the ET-B SNP in 14 children with SCD in 
relation to health care utilization for pain over the previous 24 months as noted in the 
child’s medical record, including hospitalizations, emergency room visits, and outpatient 
health care contacts. The figure shows a significant mean difference between the ET-B 
genotypes for health care utilization, with the GG genotype (M = 15.13, SD =7.77) being 
associated with higher health care utilization than the AG and AA subtypes (average of 
means = 2.38, average of SDs = 2.26), t (11) =3.55, p = .005. In contrast, The ET-A 
genotypes were not related to health care utilization in this sample. The findings from this 
study suggested that genetic variability in the ET-B receptor gene was a potential marker 
of health care utilization in children with SCD. The specific pattern of results also 
suggested a codominant model, in which each copy of the G allele conferred greater risk 
for pain. 
 Study Two: Aim and Hypothesis. The primary aim of Study Two was to 
replicate the results for the ET-B receptor using a larger sample of children with SCD, 
thereby establishing a novel marker of pain variability in SCD. The ET-B allele was 
examined in relation to health care utilization, with secondary exploratory analyses 
conducted for pain rate, intensity, and duration. Based on our preliminary data, the 
following hypothesis was made: 
 29 
 
Hypothesis: The G allele will confer greater risk for health care utilization, such 
that the GG and AG genotypes will be associated with higher rate of utilization for pain 
than the AA genotype.  
Note: Although the ET-B gene could have been examined in concert with the 
psychosocial variables in Study One, it was separated out due to the absence of prior 
research documenting this SNP as a predictor of pain in SCD. 
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Figure 2.1.. Relationship between endothelin B receptor genotypes and health care 
utilization from preliminary data. This figure depicts the relationship between ET-B 
receptor genotypes (AA, AG, or GG) in 14 children with sickle cell disease and health 
care utilization over the previous 24 months as measured by the medical record. 
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CHAPTER 3 
METHODS 
3.1 Overall Approach 
Study One and Two were undertaken concurrently using a cross-sectional design 
that included the collection of data from children with SCD and their caregivers during 
routine health visits. Children and caregivers completed measures that assessed 
demographic and psychosocial variables and pain history (Study One) and children 
provided a saliva sample for genetic analysis (Study Two). For psychosocial variables, 
children completed measures of coping and mood. Caregivers completed similar 
measures to assess coping and mood as well as a demographic questionnaire and a 
measure of family functioning. Information on additional demographic variables, medical 
status, pain, and laboratory markers of current disease status (e.g., fetal hemoglobin) were 
collected through medical record review.   
3.2 Participants and Recruitment 
Seventy-six children and youth with SCD, ages 8 to 21, and 70 caregivers 
participated in the studies (see Tables 3.1 and 3.2). This age range for children was 
chosen to maximize participation in the research while also considering the lowest age 
range that would allow for valid self-report data (our measures had been validated with 
children as young as age 8). Youth between the ages of 18 and 21 were given the choice 
of participating with or without a caregiver. This decision was made to maximize 
participation of this particular group of youth, who were more likely to attend
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hematological visits without a caregiver. Five youth chose to participate without a 
caregiver.  
Families were recruited during routine health visits at the Center for Children’s 
Cancer and Blood Disorders (CCBD) at Palmetto Richland Children’s Hospital in 
Columbia, SC. Study recruitment and enrollment occurred between April of 2012 and 
May of 2013. Eligibility for the study was determined by examining the child’s medical 
chart. After the chart review, we consulted with Dr. Carla Roberts, the attending 
hematologist, to determine if there were any reasons to postpone approaching the family 
(e.g., acute medical or psychosocial concerns). Dr. Roberts asked the families about their 
interest in the study and an investigator followed up with the family after the visit or via 
phone to set up a time to complete the procedures (typically at the child’s next scheduled 
hematological visit). During the study period, 126 families were approached and 6 were 
not interested. Reasons given included: not a good time for the family (n = 4), not enough 
time at appointments (n = 1), and no reason (n = 1). Forty-four families were interested, 
but did not participate. Reasons included the following: the family did not show up for 
their follow-up hematological visits (n = 19), the child was not scheduled to come back 
until after the study ended (n = 18), not enough time at child’s hematological visit (n = 5), 
and acute psychosocial concerns (n = 2).  
Inclusion and Exclusion Criteria. Eligible children must have received their 
primary hematological care through the CCBD. Children with major developmental 
disorders or overt neurologic disease resulting in severe cognitive limitations were 
excluded, as these conditions would limit the validity of the self-report data. Of the 
children eligible to participate by age, four percent were excluded due to cognitive or 
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developmental disorders. Participants could not be experiencing pain requiring the use of 
opioid-based drugs on the day of participation as this may have influenced their ability to 
complete self-report data on pain. If opioid drugs were used, children and their families 
were asked to participate at a later time or during their next routine visit.  
Children undergoing transfusion therapy were excluded because transfusion 
therapy can alter the natural course of pain in SCD and these children represented a small 
minority of the overall population of children with SCD at the clinic (Miller, et al., 2001). 
Of the children eligible to participate by age, eight percent were excluded due to 
transfusion therapy. In contrast, children receiving hydroxyurea, a treatment that can also 
alter the natural course of pain in SCD, were not excluded as this treatment was much 
more prevalent in the clinic population (Strouse, et al., 2008). Caregivers of children 
treated with hydroxyurea were asked to provide additional detail about the child’s pain 
history and the researcher documented treatment and pain history during the medical 
record review. In addition, the hematologist was consulted to provide ratings of 
therapeutic response to complement the medical record review.  
3.3 Measures 
 Background Information. Caregivers completed a brief demographic 
questionnaire that requested information on the child’ race and ethnicity as well as the 
caregiver’s relation to the child, race, ethnicity, marital status, and education.  
Pain and Disease Information.  Information on the child’s health status can be 
found in Table 3.1. Table 3.3 provides means and standard deviations for the pain 
outcomes.  
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 Pain History Interview. The pain history interview is a modified version of the 
Structured Pain Interview (SPI) that was validated by Gil and colleagues (1991) in 
children and adolescents with SCD ages 7 to 18 years and their caregivers. The pain 
history interview assesses recent pain status and health care utilization through separate 
child and caregiver interviews. The interview also assesses family history of chronic 
health conditions, including pain conditions, for the caregiver interview. For recent pain 
status, pain rate and health care utilization (over the past 12 months), location, average 
duration (in days), and average intensity (on a scale from 0 to 10) were noted. For health 
care utilization, children and caregivers were asked about hospitalizations, emergency 
room visits, and outpatient health care contacts (e.g., calls or visits to the clinic for pain) 
over the past 12 months. For pain intensity, children and caregivers were shown a visual 
pain scale with numerical anchors from 0 to 10 along with three verbal anchors (0 = no 
pain, 5 = moderate pain, 10 = worst pain possible). For children currently taking 
hydroxyurea, caregivers were asked to provide additional ratings of pain rate, health care 
utilization, average duration, and average intensity for the year prior to the child taking 
hydroxyurea. 
 Gil and colleagues (1991, 1993) demonstrated moderate correspondence between 
child and caregiver reports on the SPI as well as temporal stability of the measure in 
caregivers of children with SCD. In the present sample, child and caregiver ratings were 
moderately associated for pain rate (r = .32, p = .009), intensity (r = .30, p = .015), and 
duration (r = .31, p = .010). Child and caregiver ratings were more strongly associated for 
health care utilization (r = .66, p < .001).  There were no systematic differences in 
correspondence with caregiver reports between younger children (ages 8 to 12) and 
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adolescents (ages 13 and older). For younger children, the correlations with caregiver 
ratings were as follows: pain rate (r = .31), intensity (r = .46), duration (r = .31), and 
health care utilization (r = .65). For adolescents, the correlations with caregiver reports 
were as follows: pain rate (r = .33), intensity (r = .15), duration (r = .41), and health care 
utilization (r = .78).  Given only moderate associations between most child and caregiver 
ratings, final ratings were averaged between reporters in an attempt to avoid over- or 
under-estimation of pain.  
Medical Record Review. Medical record review was conducted using a structured 
coding method. Information was collected on the child’s age, gender, sickle cell 
genotype, and the most recent laboratory blood results for hematocrit and fetal 
hemoglobin. Information was also collected on potential biological covariates, including 
the presence or absence of alpha thalassemia trait and the most recent laboratory blood 
results for white blood cells and platelets. At the CCBD, hematocrit, white blood cells, 
and platelets were routinely measured at each clinic visit. Fetal hemoglobin was 
measured every two years for children ages 8 to 21 until levels reach less than 10%. For 
pain history, documented hospitalizations, emergency room visits, and outpatient health 
care contacts (e.g., calls or visits to the clinic) for pain episodes over the previous 24 
months were recorded. Although the time captured for medical record review differed 
from caregiver- and child-reported health care utilization in the pain history interview 
(i.e., 24 months versus 12 months), these measures were strongly related (r = .67). 
For children taking hydroxyurea, laboratory values for hematocrit and fetal 
hemoglobin that were closest to the start date of treatment were recorded. In addition, 
documented hospitalizations, emergency room visits, and outpatient health care contacts 
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for pain episodes in the 24 months preceding the start of treatment were recorded. This 
information was used to obtain measures of the child’s pre-hydroxyurea health status.  
Hematologist Ratings of Hydroxyurea. For children taking hydroxyurea, the 
hematologist provided ratings of therapeutic response. This information was used 
descriptively to better understand the possible impact of hydroxyurea on the study 
outcomes. For therapeutic response, the hematologist reviewed the child’s laboratory 
work since the start of treatment and provided a rating of good, partial, or no response to 
treatment. Children in the “partial response” category included those who had not yet 
reached a therapeutic dosage.  
  Psychological Variables: Child-Completed. Table 3.4 provides means, standard 
deviations, and internal consistency estimates for the psychosocial questionnaires. 
 Coping Strategies Questionnaire for Sickle Cell Disease (CSQ-SCD). The CSQ-
SCD is an 80-item questionnaire that assesses the frequency of coping behaviors children 
use to deal with pain. The CSQ-SCD was validated by Gil and colleagues (1991) for 
children and adolescents with SCD ages 7 to 17. The CSQ-SCD includes 13 subscales 
with six items each, with each item rated on a 7-point Likert scale from 0 (never) to 6 
(always) to indicate how often a strategy is used. Factor analysis has supported three 
broad subscales: Coping Attempts, Negative Thinking, and Passive-Adherence. Coping 
Attempts, which measures adaptive coping (e.g., distraction), and Negative Thinking, 
which measures maladaptive coping (e.g., catastrophic thinking), were the focus of the 
present study. Scores on the Coping Attempts scale ranged from 0 to 180, with higher 
scores representing higher coping attempts. Scores on the Negative Thinking Scale 
ranged from 0 to 144, with higher scores representing higher ratings of negative thinking. 
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In the current study, internal consistency was good to excellent for the Coping Attempts 
(α = .91) and Negative Thinking (α = .89) scales. 
 Positive and Negative Affect Scale (PANAS-C). The PANAS-C is a 27-item 
scale containing two subscales that assess positive and negative mood states. Children are 
asked to rate the extent to which they have felt different positive (e.g., happy, excited) 
and negative emotions (e.g., sad, upset) in the past week using a 5-point Likert scale 
ranging from 1 (very slightly or not at all) to 5 (extremely). Average ratings across all the 
positive and negative emotions were used to calculate overall Positive and Negative 
Mood scale scores. Scores ranged from 1 to 5, with lower scores representing lower 
ratings of positive or negative mood and higher scores representing higher ratings of 
positive or negative mood. The PANAS-C has been validated with children in grades 4 
through 8 and has established convergent validity with measures of anxiety and 
depression (Laurent, et al., 1999). In the current study, internal consistency was good to 
excellent for the Positive (α = .90) and Negative Mood (α = .86) scales. 
 Social Variables: Caregiver-Completed. 
 Coping Strategies Questionnaire-Revised (CSQ-R). The CSQ-R is a revised 27-
item version of the original Coping Strategies Questionnaire (CSQ) by Rosenstiel and 
Keefe (Rosenstiel & Keefe, 1983). The CSQ-R is considered to be a brief, parsimonious 
measure that captures the same constructs as the original CSQ. Each item on the CSQ-R 
is rated on a 7-point Likert scale from 0 (never) to 6 (always) to indicate how often a 
strategy is used. Caregivers reported how often they use coping strategies for their own 
pain (e.g., headache). Although the scale is considered to have six subscales, factor 
analysis suggests two broad factors: Active and Passive Coping. Active Coping refers to 
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adaptive coping behaviors (e.g., distraction) while Passive Coping refers to maladaptive 
coping behaviors (e.g., catastrophic thinking) for pain (Hastie, Riley, & Fillingim, 2004). 
Scores on the Active Coping scale ranged from 0 to 108, with higher scores representing 
higher ratings of active coping. Scores on the Passive Coping scale ranged from 0 to 54, 
with higher scores representing higher ratings of passive coping. These subscales are 
similar to the Coping Attempts and Negative Thinking subscales of the CSQ-SCD.  
 The CSQ-R has been validated in a large sample of healthy African-American 
adults (Hastie, et al., 2004). In the current study, internal consistency was good to 
excellent for the Active (α = .90) and Passive Coping (α = .77) scales. Caregivers who 
self-reported having a pain condition on the Pain History Interview produced lower 
ratings of active coping (M = 58.17, SD = 19.32) and higher ratings of passive coping (M 
= 28.56, SD = 10.35) versus caregivers without pain conditions (Active Coping: M = 
59.40, SD = 18.18; Passive Coping: M = 25.52, SD = 6.97); however, these differences 
were not statistically significant (p ≥ .184). 
 Positive and Negative Affect Scale - Revised (PANAS-X). The PANAS-X is a 
20-item measure that contains two subscales that assess positive and negative mood 
states. Caregivers were asked to rate the extent to which they felt different positive (e.g., 
interested, excited) and negative emotions (e.g., scared, upset) in the past week using a 5-
point Likert scale ranging from 1 (very slightly or not at all) to 5 (extremely). Average 
ratings across all the positive and negative emotions were used to calculate overall 
Positive and Negative Mood scale scores. Scores ranged from 1 to 5, with lower scores 
representing lower ratings of positive or negative mood and higher scores representing 
higher ratings of positive or negative mood. The PANAS-X has demonstrated temporal 
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stability as well as good convergent validity with measures of anxiety and depression 
(Watson, et al., 1988). In the current study, internal consistency was good for the Positive 
(α = .89) and Negative Mood (α = .87) scales.  
 McMaster Family Functioning Assessment Device (FAD). Caregivers reported 
on family functioning using the General Functioning (GF) subscale of the FAD. The GF 
is a 12-item subscale that assesses the degree to which a family functions well together as 
a unit. Caregivers rate the extent to which they strongly agree or disagree with 12 
statements on a four-point Likert scale ranging from 1 (strongly agree) to 4 (strongly 
disagree) (Epstein, Baldwin, & Bishop, 1983). Scores are averaged across the 12 items to 
produce a GF score and range from 1 to 4, with lower scores representing better family 
functioning. The subscales of the FAD, including the GF subscale, are not substantially 
influenced by social desirability. The GF subscale has also established convergent 
validity with family variables thought to indicate familial dysfunction (e.g., caregiver 
mental health problems, spousal abuse, and alcohol abuse) (Byles, Byrne, Boyle, & 
Offord, 1988).  Finally, this measure has shown very good psychometric qualities when 
used with African-American families, including families of children with SCD, with 
medium-to-large correlations with converging constructs (Guada, et al., 2010; Petrocelli, 
et al., 2003; Schatz, et al., 2008). In the current study, internal consistency was good (α = 
.83). 
3.4 Procedures 
 All study procedures, including the consent and assent process, were conducted 
by the study investigators (A.M.S. or J.S.). Institutional Review Board approval was 
obtained from Palmetto Richland Hospital, with concurrent approval from the University 
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of South Carolina. Informed consent was obtained from all caregivers and assent was 
obtained from all children. Families were told that their choice to participate in the study 
would not impact their relationship with health care staff or their treatment at the CCBD.  
Procedures for Questionnaires. Children and caregivers completed the 
demographic and psychosocial questionnaires as well as the structured pain interviews in 
a private clinic room. The pain history interview was conducted at the beginning of the 
session with the child and at the end of the session with the caregiver. Questions were 
read aloud to all children, with the exception of adolescents who indicated a preference 
for completing measures independently. For child questionnaires, one child did not 
complete the PANAS-C due to experimenter error. For caregiver questionnaires, one 
child’s caregiver was unable to complete the questionnaires and the pain history 
interview due to an acute medical illness and two caregivers did not complete the Family 
Functioning scale by mistake. Attempts were made to contact these families via phone 
and mail to complete the forms, but were unsuccessful. For the caregiver who did not 
complete the pain history interview, only the child’s ratings were used for recent pain 
status. Medical record reviews were conducted after the families’ visit. Both electronic 
and paper records were reviewed. Hematologist ratings of therapeutic response for 
hydroxyurea were also completed after the child’s visit. 
Procedures for Saliva Collection, DNA Extraction, and Genotyping. Prior to 
completing the questionnaires, approximately 1.5mL of saliva was collected in a sterile 
container from each child. Samples were preserved within one hour of collection using 1 
mL of DNAzol. The samples were then transported to a genetics laboratory, at which 
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point 20 uL Proteinase K was added for additional preservation. Samples were incubated 
overnight and refrigerated in a temperature-controlled cooling room until extraction.  
Extraction was completed using an ethanol procedure. First, 750 uL of saliva was 
added to a 1.5 mL microcentrifuge tube and centrifuged at 13,000 rpm for 15 minutes. 
The supernatant was then transferred to a new 1.5 mL microcentrifuge tube and the pellet 
was discarded. Then, 750 uL of 100% ethanol was added to the supernatant and was 
gently mixed by inversion. The samples stood at room temperature for 10 minutes and 
were then centrifuged at 13,000 rpm for 3.5 minutes. The supernatant was removed, 
leaving the pellet, and 250 uL of 70% ethanol was then added. The supernatant was 
removed again and 150 uL of distilled water was added. The solution was vortexed for a 
few seconds and the suspended DNA was allowed to incubate for 24 hours. Extracted 
DNA was stored in temperature-controlled freezers until polymerase chain reaction 
(PCR) was performed.  
A standard PCR was performed to amplify the DNA using the following 
oligonucleotide primers for the ET-B SNP: 
5'AAGATTCTGTATGATATATACAAACT3' (forward for ET-B) and 
5'ATTTCACAGGTCATTAGTGTAT3' (reverse for ET-B).  The thermocylcer was 
programmed to the following settings: initial denature (94°C, 30 seconds), denature 
(94°C, 20 seconds), annealing (47 °C, 35 seconds), extension (65°C, 45 seconds), and 
final extension (65°C, 5 minutes) with a total of 35 cycles. Amplification was confirmed 
using 0.4% Agarose gel electrophoresis. Once confirmed, unpurified PCR product was 
sent for Sanger Sequencing provided by High Throughput Genomics Center (Seattle, 
WA). Two samples were unable to be reliably sequenced due to a low DNA yield, 
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resulting in 74 total samples that were used in the final analysis. Sequencing results were 
returned in the format of chromatograms and were interpreted using Sequencher software 
(Version 5.1). An example chromatogram and interpretation can be seen in Figure 3.1. 
3.5 Statistical Analysis 
Statistical analysis was completed using SPSS, Version 19. For all analyses 
below, pain features were assessed as follows. Pain rate was an average of total 
caregiver- and child-reported pain episodes over the previous 12 months, including those 
treated at home as well as those treated via health care utilization. Pain duration and 
intensity were an average of caregiver- and child-reported ratings for the previous 12 
months. For health care utilization, two measures were used: a) an average of total 
caregiver- and child-reported health care utilization over the previous 12 months, and b) 
total health care utilization as measured by the medical record over the previous 24 
months. Alpha was set to .05 for all analyses. Due to concerns about power, no 
corrections were made for multiple comparisons.  
Study One: Analysis of Biopsychosocial Factors. For Study One Aims I and II, 
a multiple hierarchical regression approach was used to assess the contribution of 
biological factors, child psychological factors, and their interactions to pain variability, 
controlling for demographic and biological covariates (described below). Separate 
analyses were conducted for the full sample of 76 children and for the subpopulation of 
52 children with HbSS and HbSβ0 who had documented fetal hemoglobin levels. For the 
full sample, sickle cell subtype was used as the primary biological predictor. Sickle cell 
subtype was dichotomized into high (HbSS and HbSβ0; n = 52) and low risk (HbSC and 
HbSβ+; n = 24) groups using dummy codes for Aim I (i.e., 1, 0) and contrast codes for 
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Aim II (i.e., 1, -1). For the subsample of children with HbSS and HbSβ0, hematocrit and 
fetal hemoglobin were used as the primary biological predictors. Separate analyses were 
conducted for pain rate, intensity, duration, and the two health care utilization outcomes. 
Both the full sample and subsample models were used to evaluate the hypotheses. 
For Aim I, the first step of all regression models contained demographic variables 
(age and gender). The second step contained biological variables (sickle cell risk group or 
hematocrit and fetal hemoglobin). The third step contained child psychological variables 
(coping and mood). The following biological covariates were also examined for the 
subsample of children with HbSS and HbSβ0: alpha thalassemia trait, platelets, and white 
blood cells. These variables were added prior to step 2 if they had a correlation ≥ .20 with 
the pain outcomes. Hypotheses were examined by evaluating the ∆F statistic at each step 
and by comparison of effect sizes using R2 values to understand the proportion of 
variance accounted for by biological and child psychological variables to different pain 
features. Hypothesis 1 was supported by a significant amount of variance accounted for 
by biological variables and/or an effect size of R2 of .05 for pain rate and health care 
utilization. Hypothesis 2 was supported by a significant amount of variance accounted for 
by child psychological factors for pain intensity and health care utilization and/or effect 
sizes of .12 and .08, respectively. Analyses for pain duration were viewed as exploratory. 
For Aim II, the order of variables entered into the model was the same; however, 
the final step contained the interaction terms for biological and child psychological 
variables. In addition, only child psychological variables that demonstrated a correlation 
≥ .20 were examined as main effects and interactions with biological predictors. This 
approach led to a more parsimonious model and restricted the number of interactions to 
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only those likely to have a robust effect.  In addition, age and gender were only included 
if they also met the .20 criterion, in order to conserve degrees of freedom. All continuous 
predictors were mean centered and sickle cell risk group was centered using contrast 
codes. Similar to Aim I, hypotheses were examined by focusing on both statistical 
significance (i.e., ∆F statistic) and effect sizes. Models with multiple interaction terms 
were evaluated to determine which terms were likely to be responsible for the effect (i.e., 
statistical significance or trend for one or more terms). If this was not apparent, all terms 
were followed up with simple slopes and graphical analysis. Hypothesis 3 was supported 
by the absence of a significant interaction and/or R2 values of .01 or less for biological 
and child psychological factors.  Hypothesis 4 was supported by significant interaction 
terms for biological and child psychological factors and/or R2 values of .02 or higher and 
by subsequent graphical and statistical analysis supporting a synergistic or buffering 
effect.  
For Aim III, the focus was on caregiver coping, mood, and family functioning in 
relation to child psychological variables and pain outcomes. Correlations were conducted 
to determine if mediation models were likely to be supported in future studies. 
Specifically, correlations were evaluated to determine whether the effects of the family 
environment on pain outcomes were likely to be mediated by child psychological 
variables. Hypothesis 5 was supported by statistically significant correlations between 
caregiver coping and mood and child coping and mood, with child coping and mood 
directly mirroring caregiver coping and mood. Hypothesis 6 was supported by 
statistically significant correlations between family functioning and child coping attempts 
and negative thinking. Hypothesis 7 was supported by statistically significant correlations 
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between caregiver coping, mood, family functioning and health care utilization for pain. 
For pain outcomes, the focus was on health care utilization, with additional exploratory 
analyses conducted with pain rate, intensity, and duration.  
 Study Two: Genetic Association Analysis. Allele frequencies were examined 
using chi-square analysis to establish Hardi-Weinberg equilibrium, a principle that is 
used to determine whether allele distributions are consistent with what would be expected 
in a population. Linear regression was then used to examine relationships between the 
ET-B genotypes and pain variability, with a primary focus on health care utilization. 
Additional exploratory analyses were examined between the ET-B genotypes and 
additional pain features (pain rate, intensity, and duration). A codominant model was 
used to analyze the data, consistent with preliminary data. A codominant model is also 
considered to be a parsimonious, yet powerful model for detecting associations for 
quantitative traits when the inheritance pattern has not been confirmed for a specific 
population (Lettre, Lange, & Hirschhorn, 2007). The codominant model resulted in two 
coefficients that were dummy coded (i.e., 1, 0) to compare the G/G and the A/G 
genotypes to the A/A genotype.  Hypothesis 8 was supported if both coefficients 
suggested higher health care utilization for children with the G allele, with the G/G and 
A/G genotypes conferring greater risk for health care utilization for pain than the A/A 
genotype. 
 As with Study One, separate analyses were conducted for the full sample and the 
subset of children with HbSS and HbSβ0. Biserial correlations were used to determine 
initial relationships. For both samples, age and gender were examined as potential 
covariates. In addition, hematocrit, fetal hemoglobin, alpha thalassemia trait, white blood 
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cells, and platelet count were considered as covariates for the subsample. Covariates with 
correlations ≥ .20 were included in the models.  If no covariates met this criterion, 
correlations between the genotypes and pain outcomes were used in lieu of linear 
regression to simplify the results. 
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Table 3.1. 
Demographic and Medical Characteristics of Children 
 
 
Characteristics N = 76 
Age (M, SD) 
Gender (n) 
    Male 
    Female 
Race* (n) 
    African American 
    African International 
    White 
    American Indian/Alaska Native 
Ethnicity (n) 
    Hispanic, Latino, or Spanish Origin 
Insurance Status 
    Medicaid only 
    Medicaid and private insurance 
    Private insurance only 
Sickle Cell Subtype (n) 
    HbSS 
    HbSC 
    HbSβ0   
    HbSβ+ 
Presence alpha thalassemia trait (n) 
Average hematocrit (M, SD) 
Average fetal hemoglobin (M, SD) 
Average white blood cells (M, SD) 
Average platelets (M, SD) 
Currently taking hydroxyurea (n) 
    Good therapeutic response 
    Partial therapeutic response 
    No therapeutic response 
14.05, 3.26 
 
44 
32 
 
76 
1 
1 
3 
 
2 
 
47 
13 
16 
 
48 
19 
4 
5 
8 
27.51, 4.96 
11.27, 9.82 
9.51, 3.15 
387.50, 183.57 
40 
18 
9 
13 
*Participants were able to mark multiple selections. 
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Table 3.2. 
Demographic Characteristics of Caregivers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Participants were able to mark multiple selections. 
 
 
 
 
 
Characteristics (n) N = 70 
Caregiver Relation to Child 
    Mother 
    Father 
    Grandparent 
Caregiver Race* 
    African American 
    African International 
    White 
    American Indian/Alaska Native 
Ethnicity 
    Hispanic, Latino, or Spanish Origin 
Caregiver Education 
    Some high school 
    High school diploma 
    Some college 
    College degree 
    More than college degree 
Marital Status* 
    Single and never married 
    In a relationship/living with someone 
    Married 
    Separated 
    Divorced 
    Widowed 
    No response 
Caregiver Health Status 
    Caregiver with Pain Condition 
 
62 
4 
4 
 
70 
1 
1 
5 
 
1 
 
6 
22 
28 
13 
6 
 
27 
3 
19 
7 
7 
4 
3 
 
18 
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Table 3.3. 
Descriptive Information on Pain Outcomes 
 
 
Pain Outcomes M, SD 
Caregiver and Child Report  
    Pain rate (total previous 12 months) 7.52, 12.27 
    Average pain intensity (0 to 10; previous 12 months) 7.20, 1.70 
    Average pain duration (in days; previous 12 months) 2.67, 2.83 
    Health care utilization (previous 12 months) 
        Total 
        Hospitalizations 
        Emergency Room Visits 
        Outpatient Visits/Calls to Physician 
 
6.25, 9.16 
1.00, 1.81 
1.48, 2.64 
4.24, 7.53 
Medical Record 
    Health care utilization (previous 24 months) 
        Total 
        Hospitalizations 
        Emergency Room Visits 
        Outpatient Visits/Calls to Physician 
 
 
3.41, 4.02 
1.64, 2.53 
1.07, 1.80 
.70, 1.84 
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Table 3.4. 
Descriptive Information on Psychosocial Variables for Children and Caregivers 
 
 
Psychosocial Variables α M, SD 
Child-Level Variables   
    Coping Strategies Questionnaire for SCD (CSQ-SCD) 
        Coping Attempts 
        Negative Thinking 
    Positive and Negative Affect Scale for Children (PANAS-C)  
        Positive Mood 
        Negative Mood 
 
.91 
.89 
 
.90 
.86 
 
81.27, 31.09 
53.90, 25.62 
 
3.48, .93 
1.68, .58 
Caregiver-Level Variables   
    Coping Strategies Questionnaire – Revised (CSQ-R) 
        Active Coping 
        Passive Coping 
    Positive and Negative Affect Scale – Revised (PANAS-X) 
        Positive Mood 
        Negative Mood 
 
.90 
.77 
 
.89 
.87 
 
58.74, 18.77 
25.77, 7.96 
 
3.75, .80 
1.78, .70 
Family-Level Variable   
    McMaster Family Functioning Device 
        General Functioning  
 
.83 
 
1.68, .44 
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Figure 3.1. Example chromatogram demonstrating genotype results for the endothelin B 
receptor single nucleotide polymorphism. The single nucleotide polymorphism locus is 
highlighted in blue. A large, single black peak represents two copies of the G allele; a 
moderate, single green peak represents two copies of the A allele; and the combination of 
one black and one green peak overlapping represents the heterozygote AG group. 
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CHAPTER 4 
STUDY ONE RESULTS 
 Study One examined the role of biological and psychosocial factors in relation to 
multiple pain outcomes in pediatric SCD. The following sections describe results for each 
of the primary aims. For each aim, additional analyses were completed to complement or 
address key limitations from the original analysis. These analyses are noted as 
“supplemental” and are described after the primary results of each aim.  
4.1 Regression Assumptions  
 Regression assumes independence of errors, normality of residuals, absence of 
outliers, absence of multicollinearity, additivity, linearity, and homoscedasticity of 
residuals. When evaluating assumptions, three principles were prioritized: (a) 
maintaining the interpretability of the findings, in terms of the scaling of the variables, (b) 
identifying models with the highest degree of stability and concordance with model 
assumptions, and (c) using all of the data available to preserve power. The two primary 
issues identified for Study One were non-normality of residuals and the presence of 
outliers. 
 Normality of residuals was assessed via histograms of residuals for each model. 
Residual distributions for the models involving pain rate were consistently leptokurtic 
and the model for caregiver- and child-reported health care utilization was consistently 
leptokurtic and positively skewed. These deviations were likely due to non-normal 
distributions for both variables, which were positively skewed. Influential cases also
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 posed an issue for these specific pain features. Case diagnostics were used to examine 
the presence of influential cases for each predictor, using a DFBETA criterion of +/- 2 
√k/n (where k equals number of predictors and n equals sample size) for the full sample 
and a value of 1 for the subsample. The models for pain rate and caregiver- and child-
reported health care utilization demonstrated the greatest number of influential cases, 
particularly for Aim One (ranging from 3 to 6 cases), with conflicting results obtained 
with the deletion of these cases individually. 
 Given concerns about non-normality of residuals and influential cases, these two 
pain features (pain rate and caregiver- and child-reported health care utilization) were 
log-transformed. The models with log-transformed outcomes were no longer influenced 
by individual cases. In addition, all of the models demonstrated normal residual 
distributions with the transformation. To aid in interpretation, significant coefficients and 
interactions were described using the original coefficients. The results tables include the 
original, untransformed and log transformed beta coefficients and standard errors.   
 In addition to these general issues with influential cases, there was a single 
influential case for pain duration (an 11 year-old girl with HbSC who self-reported 36.5 
days for pain duration) that dramatically altered the results for the full sample models for 
Aim One and Two (this case was not included in the subsample analysis because of the 
child’s sickle cell subtype). The child’s average score with caregiver report (21.75) was 
far outside the mean of 2.67 for the sample, so the caregiver pain duration score (7) was 
used instead. The reason for this child’s report of such a long duration is unclear, but it is 
possible that the child had difficulty discriminating between distinct episodes and instead 
grouped multiple pain episodes together.   
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 Independence of errors was assessed using the Durbin-Watson statistic. Each 
model’s Durbin-Watson statistic was compared to a statistical table with upper and lower 
limits for values based on k number of predictors and sample size. The focus of this 
assessment was on positive autocorrelation, which could have posed an issue for the 
models due to the presence of several sibling groups (9 sibling groups; n = 19). None of 
the models exceeded the lower limits for this statistic (Durbin-Watson ranged from 1.51 
to 2.28); thus, independence of errors was assumed to be adequate.  
 For multicollinearity, correlations above .50 were presumed to present issues for 
the regression. Hematocrit and fetal hemoglobin exceeded this value for analyses 
involving the subsample of participants with HbSS and HbSβ0 (r = .58). For Aim I, both 
variables were included together as the focus was on comparisons of cumulative effect 
size for biological factors. For Aim II, the primary analysis included these factors 
together to reduce the number of models examined; however, a supplemental analysis 
examining hematocrit and fetal hemoglobin in separate models was conducted to 
determine whether multicollinearity was an issue. Finally, residual plots were used to 
assess linearity and homoscedasticity; no curvilinear patterns or systematic deviations 
from homoscedasticity were identified. 
4.2 Aim I: Compare the effect sizes of biological and psychological factors in 
relation to multiple pain outcomes in pediatric SCD  
 Tables 4.1 and 4.4 provide correlation tables for the covariates, predictors, and 
pain outcomes for the full sample and subsample of children with HbSS and HbSβ0, 
respectively. Please note that the overall statistical significance of the full regression 
models is provided to give the reader a sense of how well the combination of biological 
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and psychological factors predicted each pain feature; however, the focus of the results is 
on the change in explained variance with each set of biological and psychological 
predictors (i.e., the incremental change in R2 or ∆F statistic). This approach was taken 
because it provides more information about which predictors are most relevant to specific 
pain features, which may help with future research planning. In addition, please note that 
hypotheses 1 and 2 could be supported by the model demonstrating a significant amount 
of variance for the predictors or by meeting the hypothesized effect size estimate. 
 Full Sample. Table 4.2 provides multiple hierarchical regression results for pain 
rate, intensity, and duration. Table 4.3 provides results for both health care utilization 
outcomes.  
 Pain rate was log-transformed due to six influential cases that resulted in 
conflicting results. The log-transformed model demonstrated no influential cases and also 
conformed to the assumption of normality of residuals. Results are presented using the 
log-transformed results; however, significant coefficients are described using the original 
unstandardized beta coefficients, which are more interpretable. The overall regression 
model was significant, F (7, 67) = 2.31, p =. 036, with the model explaining 20% of the 
variance in pain rate overall. After controlling for age and gender, sickle cell risk group 
did not contribute a significant amount of variance to the model, ∆F (1, 71) = 1.52, p = 
.221, ∆R2 = .02, and the R2 was less than .05; thus, hypothesis 1 was not supported for 
pain rate. The addition of child psychological variables contributed a significant amount 
of variance to the model, ∆F (4, 67) = 3.28, p = .016, ∆R2 = .16. Positive mood was also a 
significant individual predictor, t (1, 74) = -2.30, p = .025. Using results from the 
original, untransformed model, for every one-point increase in positive mood, there was a 
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3.01 decrease in pain rate. Negative thinking approached significance as an individual 
predictor, t (1, 74) = 1.94, p = .056. 
 For pain intensity, the overall regression model was not significant, F (7, 67) = 
1.37, p = .234, with the model explaining 13% of variance overall. After controlling for 
age and gender, sickle cell risk group contributed a significant amount of variance to the 
model, ∆F (1, 71) = 4.33, p = .041, ∆R2 = .06.  According to the unstandardized beta 
coefficient, children with high-risk subtypes had a .89 higher pain intensity rating versus 
those with low-risk subtypes. The addition of child psychological variables did not 
contribute a significant amount of variance to the model, ∆F (4, 67) = 0.40, p = .807, ∆R2 
= .02, and the R2 value was far below the hypothesized estimate of .12; thus, hypothesis 2 
was not supported for pain intensity. For pain duration, the overall regression model was 
not significant, F (7, 67) = 0.91, p = .505, with the model explaining 9% of the variance 
overall. After controlling for age and gender, sickle cell risk group did not contribute a 
significant amount of variance to the model, ∆F (1, 70) = 0.01, p = .943, ∆R2 = .00. The 
addition of child psychological variables also did not contribute a significant amount of 
variance to the model, ∆F (4, 67) = 1.55, p = .197, ∆R2 = .09. Although the effect size 
was fairly large, there were no notable individual predictors. 
 Caregiver- and child-reported health care utilization was log-transformed due to 
three influential cases that resulted in conflicting results. The log-transformed model 
demonstrated no influential cases and also conformed to the assumption of normality of 
residuals. As with pain rate, results are presented using the log-transformed results; 
however, significant coefficients are described using the original unstandardized beta 
coefficients, which are more interpretable. For the caregiver- and child-reported health 
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care utilization variable, the overall regression model was significant, F (7, 67) = 2.39, p 
= .030, with the model explaining 20% of the variance overall. After controlling for age 
and gender, sickle cell risk group did not contribute a significant amount of variance to 
the model, ∆F (1, 71) = 2.35, p = .130, ∆R2 = .03, and the R2 value was lower than the 
hypothesized estimate of .05; thus, hypothesis 1 was not supported for caregiver- and 
child-reported health care utilization. The addition of child psychological variables 
contributed a significant amount of variance to the model, ∆F (4, 67) = 2.80, p = .033, 
∆R2 = .13, and the R2 value was greater than .08, providing support for hypothesis 2 for 
caregiver- and child-reported health care utilization. Positive mood was a significant 
individual predictor of health care utilization, t (1, 74) = -2.33, p = .023. Using results 
from the original, untransformed model, for every one-point increase in positive mood, 
there was a 2.45 decrease in health care utilization. 
 For the medical record health care utilization variable, the overall regression 
model approached significance, F (7, 67) = 2.00, p = .069, with the model explaining 
17% of the variance overall. After controlling for age and gender, sickle cell risk group 
approached significance as a contributor of variance to the model, ∆F (1, 71) = 3.59, p = 
.062, ∆R2 = .05, and the R2 value was .05; thus, hypothesis 1 for medical record health 
care utilization was supported. The addition of child psychological variables also 
approached significance as a contributor of variance to the model, ∆F (4, 67) = 2.10, p = 
.090, ∆R2 = .10, and the R2 value was greater than .08; thus, hypothesis 2 for medical 
record health care utilization was also supported. Although the overall effect of child 
psychological variables approached significance, there were no notable individual 
predictors.  
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 Sickle Cell Anemia and Sickle Cell Beta-0-Thalassemia. Tables 4.5 and 4.6 
provide multiple hierarchical regression results for pain rate, intensity, and duration. 
Table 4.7 provides results for both health care utilization outcomes.  
 Similar to the full sample model, pain rate was log-transformed due to three 
influential cases that resulted in conflicting results. The log-transformed model 
demonstrated no influential cases and also conformed to the assumption of normality of 
residuals. Results are presented using the log-transformed results. For pain rate, the 
overall regression model was not significant, F (9, 41) = 1.14, p = .361, with the model 
explaining 20% of the variance overall. After controlling for age, gender, and alpha 
thalassemia trait, the addition of hematocrit and fetal hemoglobin did not contribute a 
significant amount of variance to the model, ∆F (2, 45) = 1.00, p =. 376, ∆R2 = .04, and 
the R2 value was less than .05; thus, hypothesis 1 was not supported for pain rate. The 
addition of child psychological variables also did not contribute a significant amount of 
variance to the model, ∆F (4, 41) = 1.44, p =. 237, ∆R2 = .11. Although the effect size 
was fairly large, there were no notable individual predictors.  
 For pain intensity, the overall regression model was not significant, F (9, 41) = 
0.66, p = .739, with the model explaining 13% of the variance overall. After controlling 
for age, gender, and platelet count, the addition of hematocrit and fetal hemoglobin did 
not contribute a significant amount of variance to the model, ∆F (2, 45) = 1.69, p =. 196, 
∆R2 = .07; however, the R2 value was fairly large and fetal hemoglobin approached 
significance as an individual predictor, t (1, 50) = -1.73, p = .090. The addition of child 
psychological variables did not contribute a significant amount of variance to the model, 
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∆F (4, 41) = 0.07, p = .992, ∆R2 = .01, and the R2 value was far below the hypothesized 
estimate of .12; thus, hypothesis 2 was not supported for pain intensity. 
 For pain duration, the overall regression model was not significant, F (8, 42) = 
0.90, p = .522, with the model explaining 15% of the variance overall. After controlling 
for age and gender, the addition of hematocrit and fetal hemoglobin approached 
significance in contributing variance to the model, ∆F (2, 46) = 2.60, p = .085, ∆R2 = .10, 
and the R2 value was fairly large. Fetal hemoglobin was significant as an individual 
predictor, t (1, 50) = -2.23, p = .031, and there was a trend for hematocrit as a significant 
predictor of pain duration, t (1, 50) = 1.67, p = .102. According to the unstandardized 
beta coefficient, for every one-percent increase in fetal hemoglobin, there was a .07 
decrease in pain duration.  The addition of child psychological variables did not 
contribute a significant amount of variance to the model, ∆F (4, 42) = 0.45, p = .771, ∆R2 
= .04. 
 Caregiver- and child-reported health care utilization was log-transformed due to 
four influential cases that resulted in conflicting results. The log-transformed model 
demonstrated no influential cases and also conformed to the assumption of normality of 
residuals. Results are presented using the log-transformed results.  The overall regression 
model was not significant, F (8, 42) = 1.33, p = .256, with the model explaining 20% of 
the variance overall.  After controlling for age and gender, the addition of hematocrit and 
fetal hemoglobin did not contribute significant variance to the model, ∆F (2, 46) = 1.14, p 
= .330, ∆R2 = .05; however, the R2 value was .05, providing support for hypothesis 1. The 
addition of child psychological variables also did not contribute a significant amount of 
variance to the model, ∆F (4, 42) = 1.99, p = .113, ∆R2 = .15; however, the R2 value was 
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higher than .08.  Thus, hypothesis 2 was also supported for this outcome. Positive mood 
approached significance as an individual predictor of health care utilization, t (1, 50) = -
1.73, p = .092. 
 For the medical record health care utilization variable, the overall regression 
model was significant, F (8, 42) = 2.46, p = .028, with the model explaining 32% of the 
variance overall. After controlling for age and gender, hematocrit and fetal hemoglobin 
did not contribute a significant amount of variance to the model, ∆F (2, 46) = 0.21, p = 
.811, ∆R2 = .01, and the R2 value was less than .05; thus, hypothesis 1 was not supported 
for medical record health care utilization.  In contrast, the addition of child psychological 
variables contributed a significant amount of variance to the model, ∆F (2, 42) = 3.48, p 
= .015, ∆R2 = .23, and the R2 value easily exceeded .08; thus, hypothesis 2 was supported 
for this outcome. Positive mood was also a significant individual predictor of health care 
utilization, t (1, 50) = -2.09, p = .043. According to the unstandardized beta coefficient, 
for every one-point increase in positive mood, there was a 1.42 decrease in health care 
utilization.  
 Supplemental Analyses: Pre-Hydroxyurea Relationships with Biological Risk 
Factors. The majority of children (n = 40) with HbSS and HbSβ0 were treated with 
hydroxyurea at the time of the study. Due to the possibility of hydroxyurea influencing 
both the hematological variables (hematocrit and fetal hemoglobin) and pain outcomes, it 
is possible that the effect of biological risk on pain outcomes was attenuated. Thus, these 
relationships were evaluated again using information from caregivers and the medical 
record regarding pre-hydroxyurea values for biological variables and pain outcomes. For 
the full sample, correlations were conducted between sickle cell risk group and pain 
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outcomes, with the pre-hydroxyurea pain outcomes used for children taking hydroxyurea 
at the time of the study (see Table 4.8). The correlation values were used to calculate R2 
values for sickle cell risk group and each pain outcome. For the subsample of children 
with HbSS and HbSβ0, pre-hydroxyurea measures of hematocrit and fetal hemoglobin 
and pain outcomes were used and the variables were entered into a regression model to 
calculate R2 values (see Table 4.9).   
 Pre-Hydroxyurea Analysis for Sickle Cell Risk Group (Full Sample). For pain 
rate, the R2 value for sickle cell risk group was .03, which is higher than the original 
analysis, but still below the hypothesized value of .05 and not statistically significant; 
thus, similar to the original analysis, hypothesis 1 was not supported. For pain intensity, 
the R2 value was .11, which is higher than the original analysis. Similar to the original 
analysis, the correlation was statistically significant. For pain duration, the R2 value was 
less than .01, which is lower than the original analysis. For caregiver- and child-reported 
health care utilization, the R2 value was .06, which is higher than the original analysis 
and, in contrast to Aim 1, does support hypothesis 1. Finally, for medical record health 
care utilization, the R2 value was also .06, which is close to the original analysis and 
similarly supports hypothesis 1.  
 Pre-Hydroxyurea Analysis for Hematocrit and Fetal Hemoglobin (Sickle Cell 
Anemia and Sickle Cell Beta-0-Thalassemia). For pain rate, the R2 value was .04 for 
hematocrit and fetal hemoglobin, which is larger than the original analysis; however, this 
value is still under the hypothesized value of .05. Thus, similar to Aim I, hypothesis 1 
was not supported. For pain intensity, the R2 for hematocrit and fetal hemoglobin was .14, 
which is higher than the primary analysis. In addition, fetal hemoglobin was a significant 
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individual predictor. Although the value is higher, the results were fairly similar to the 
original analysis described in Aim I. For pain duration, the R2 value was .09 for 
hematocrit and fetal hemoglobin, which is similar to the original analysis. For caregiver- 
and child-reported health care utilization, the R2 value was .03, which is lower than the 
original analysis. Finally, for medical record health care utilization, the R2 value of .07 
for hematocrit and fetal hemoglobin was higher than the original analysis and, in contrast 
to the results for Aim 1, supports hypothesis 1.  
4.3 Aim II: Explore interrelationships among biological and psychological factors 
 For Aim II, age and gender were included for the model for medical record health 
care utilization in the subsample because these variables met the ≥ .20 correlation 
criterion. These variables were excluded from other models in order to conserve degrees 
of freedom. As noted previously, in order to reduce the number of interactions examined, 
psychological variables were selected for models if they had a correlation ≥ .20. For 
interactions, please note that interaction terms were pursued based on statistical 
significance or an effect size greater than R2 = .02. This approach was taken to evaluate 
interactions that may be meaningful despite having a small effect size. 
 Full Sample. Table 4.10 provides results for multiple hierarchical regressions for 
pain rate and duration with the selected variables and their interactions. Table 4.11 
provides results for the health care utilization variables. For pain intensity, none of the 
psychological predictors demonstrated a correlation ≥ .20; thus, interactions were not 
evaluated for this pain outcome. 
 In order to be consistent with the model from Aim I, pain rate was log-
transformed. Results are presented using the log-transformed results. For this model, in 
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addition to sickle cell risk group, negative thinking and positive mood were entered into 
the model along with two interaction terms for each child psychological variable with 
sickle cell risk group. The overall regression model was significant, F (5, 69) = 3.07, p =. 
015, with the model explaining 18% of the variance overall; however, the interaction 
terms did not contribute a significant amount of variance, ∆F (1, 73) = 0.23, p = .795, 
∆R2 < .01, and the R2 value was less than .01. For main effects, sickle cell risk group did 
not contribute a significant amount of variance to the model, ∆F (1, 73) = 2.19, p = .143, 
∆R2 = .03. The addition of negative thinking and positive affect contributed a significant 
amount of variance to the model, ∆F (2, 71) = 6.35, p =. 003, ∆R2 = .15. Negative 
thinking was a significant individual predictor, t (1, 74) = 2.55, p = .013. Positive mood 
was also a significant individual predictor, t (1, 74) = -2.06, p = .043. These results 
provide support for hypothesis 3 (an additive effect) for pain rate.  
 For pain duration, in addition to sickle cell risk group, positive mood was entered 
into the model along with one interaction term for positive mood with sickle cell type 
group. The overall regression model was not significant, F (3, 71) = 1.75, p = .164, with 
the model explaining 7% of the variance overall. The addition of the interaction term did 
not contribute a significant amount of variance to the model, ∆F (1, 71) = 2.32, p = .133, 
∆R2 = .03; however, the R2 value was greater than .01.  
 This interaction was probed further via graphical analysis and simple slopes. As 
shown in Figure 4.1, for children with low-risk subtypes, higher positive mood was 
related to lower pain duration (B = -.80), whereas the slope was relatively flat for those 
with high-risk subtypes (B = -.10). For main effects, sickle cell risk group did not 
contribute a significant amount of variance to the model, ∆F (1, 73) = 0.01, p = .945, ∆R2 
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= .00. The addition of positive mood approached significance as a contributor of variance 
to the model, ∆F (1, 72) = 2.89, p = .094, ∆R2 = .04. Although these results suggest an 
interactive effect, they were not in the hypothesized direction for hypothesis 4.  
 In order to be consistent with the model from Aim One, caregiver- and child-
reported health care utilization was log-transformed. Results are presented using the log-
transformed results; however, for interactions, simple slopes were calculated using the 
original unstandardized beta coefficients. For this model, in addition to sickle cell risk 
group, negative thinking and positive mood were entered into the model along with two 
interactions terms for each psychological variable with sickle cell risk group. The overall 
regression model was significant, F (5, 69) = 3.91, p = .004, with the model explaining 
22% of the variance overall. The interaction terms did not contribute a significant amount 
of variance to the model, ∆F (2, 69) = 1.22, p = .302, ∆R2 = .03; however, the R2 value 
was greater than .01.  
 These interactions were probed further via graphical analysis and simple slopes. 
As shown in Figures 4.2 and 4.3, the difference between children with high- versus low-
risk subtypes was a change in slope, such that children with low-risk subtypes had a 
stronger relationships between negative thinking (B = .08) and positive mood (B = -2.56) 
with health care utilization versus children with high-risk subtypes (Negative Thinking: B 
= .05; Positive Mood: B = -2.14). For main effects, sickle cell risk type contributed a 
significant amount of variance to the model, ∆F (1, 73) = 3.85, p = .054, ∆R2 = .05. The 
addition of child psychological variables also contributed a significant amount of 
variance to the model, ∆F (2, 71) = 6.30, p = .003, ∆R2 = .14, and positive mood was a 
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significant individual predictor, t (1, 74) = -2.95, p = .004. Although these results suggest 
an interactive effect, they were not in the hypothesized direction for hypothesis 4. 
 For the medical record health care utilization variable, in addition to sickle cell 
risk group, negative thinking and positive mood were entered into the model along with 
two interactions terms for each psychological variable with sickle cell risk group. The 
overall regression model was significant, F (5, 69) = 2.95, p = .018, with the model 
explaining 18% of the variance overall. The interaction terms did not contribute a 
significant amount of variance to the model, ∆F (2, 69) = 1.59, p = .211, ∆R2 = .04; 
however, the R2 was greater than .01.  
 These interactions were probed further via graphical analysis and simple slopes. 
As shown in Figures 4.4 and 4.5, the difference between children with high- versus low-
risk subtypes was a change in slope, such that children with high-risk subtypes had 
stronger relationships between negative thinking (B = .05) and positive mood (B = -1.70) 
with health care utilization versus children with low-risk subtypes (Negative Thinking: B 
= .01; Positive Mood: B = -.30). For main effects, sickle cell risk group approached 
significance as a contributor of variance to the model, ∆F (1, 73) = 3.45, p = .067, ∆R2 = 
.05. The addition of child psychological variables contributed a significant amount of 
variance to the model, ∆F (2, 71) = 3.82, p = .027, ∆R2 = .09. Positive mood was also a 
significant predictor of health care utilization, t (1, 74) = -2.14, p = .036. These results 
suggest an interactive effect in the hypothesized direction, supporting hypothesis 4.  
 Sickle Cell Anemia and Sickle Cell Beta-0-Thalassemia. Tables 4.12 and 4.13 
provide multiple hierarchical regression results for pain rate and both health care 
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utilization outcomes. For pain intensity and duration, none of the psychological variables 
reached a correlation value of ≥ .20, so these models were not examined. 
 In order to be consistent with the model from Aim I, results for pain rate are 
presented using the log-transformed variable. For this model, two interaction terms were 
added for negative thinking and hematocrit and negative thinking and fetal hemoglobin. 
The overall regression model was not significant, F (6, 44) = 1.18, p = .332, with the 
model explaining 14% of the variance overall. The addition of interaction terms did not 
contribute a significant amount of variance to the model, ∆F (2, 44) = 0.11, p = .893, ∆R2 
< .01, and the R2 was less than .01. For main effects, after controlling for alpha 
thalassemia trait, the addition of hematocrit and fetal hemoglobin did not contribute a 
significant amount of variance to the model, ∆F (2, 47) = 1.06, p = .356, ∆R2 = .04. The 
addition of negative thinking also did not contribute a significant amount of variance to 
the model, ∆F (1, 46) = 2.57, p = .115, ∆R2 = .05. These results support an additive effect 
(hypothesis 3) for pain rate. 
 In order to be consistent with the model from Aim I, results for caregiver- and 
child-reported health care utilization are presented using the log-transformed variable; 
however, for interactions, simple slopes were calculated using the original unstandardized 
beta coefficients. For the caregiver- and child-reported health care utilization variable, 
two interaction terms were added for positive mood and hematocrit and positive mood 
and fetal hemoglobin. The overall regression model was significant, F (5, 45) = 2.44, p = 
.048, with the model explaining 21% of the variance overall. The addition of interaction 
terms did not contribute a significant amount of variance to the model, ∆F (2, 48) = 1.53, 
p = .227, ∆R2 = .05; however, the R2 was greater than .01.  
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 These interactions were probed further using graphical analysis and simple slopes 
calculated at the 25th and 75th percentiles of hematocrit and fetal hemoglobin. As shown 
in Figures 4.6 and 4.7, the difference between children with high versus low levels of 
hematocrit and fetal hemoglobin was a change in slope, such that children with low levels 
of hematocrit (B = -5.36) and fetal hemoglobin (B = -3.20) had stronger relationships 
between positive mood and health care utilization versus those with high levels of 
hematocrit (B = -1.40) and fetal hemoglobin (B = -2.22). For main effects, the addition of 
hematocrit and fetal hemoglobin did not contribute a significant amount of variance to 
the model, ∆F (2, 48) = 1.24, p = .298, ∆R2 = .05. The addition of positive mood was a 
significant contributor of variance to the model, ∆F (1, 47) = 6.20, p = .016, ∆R2 = .11. 
Although these results suggest an interactive effect, the direction of effects is unclear in 
terms of biological risk (see Discussion).  
 For medical record health care utilization, six interaction terms were added for 
coping attempts, positive mood, and negative mood with hematocrit and fetal 
hemoglobin. The overall regression model approached significance, F (13, 37) = 1.94, p 
= .057, with the model explaining 41% of the variance overall. Age and gender were 
included as covariates. The addition of interaction terms did not contribute a significant 
amount of variance, ∆F (6, 37) = 1.05, p = .408, ∆R2 = .10; however, the R2 value was 
greater than .01 and the interaction term for positive mood and hematocrit approached 
significance, t (1, 49) = 1.93, p = .062.  
 This interaction was probed further using graphical analysis and simple slopes 
calculated at the 25th and 75th percentiles of hematocrit. As shown in Figure 4.8, the 
difference between children with high versus low levels of hematocrit was a change in 
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slope, such that children with low levels of hematocrit had a stronger relationship 
between positive mood and health care utilization (B = -3.57) versus those with high 
levels of hematocrit (B = -0.60). For main effects, the addition of hematocrit and fetal 
hemoglobin did not contribute a significant amount of variance to the model, ∆F (2, 46) = 
0.21, p = .811, ∆R2 = .02. In contrast, the addition of child psychological variables did 
contribute a significant amount of variance to the model, ∆F (3, 43) = 4.33, p = .009, ∆R2 
= .21. Positive mood was also a significant individual predictor, t (1, 49) = -2.33, p = 
.024, and negative thinking approached significance as an individual predictor, t (1, 49) = 
1.82, p = .076.  Although these results suggest an interactive effect, the direction of 
effects is unclear in terms of biological risk (see Discussion). 
 Supplemental Analysis: Examining Separate Models for Hematocrit and 
Fetal Hemoglobin. Due to concerns about multicollinearity between hematocrit and fetal 
hemoglobin, the same models above for the subsample were analyzed again with these 
variables entered individually into separate models (see Tables 4.14 and 4.15). Consistent 
with the original model, the models did not suggest an interaction between hematocrit or 
fetal hemoglobin with negative thinking (R2 for interactions = .00 for both models) for 
pain rate. Similarly, the models continued to suggest that the strongest potential 
interaction effect for medical record health care utilization was between hematocrit and 
positive mood. For caregiver- and child-reported health care utilization, the models 
continued to suggest potential interactions for both hematocrit and fetal hemoglobin and 
positive mood, consistent with the original model; however, of note is that each of these 
interaction terms approached significance when entered into separate models, whereas 
neither term approached significance when combined in the original model. This finding 
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suggests that multicollinearity likely attenuated the effects of the interaction terms in the 
original model for caregiver- and child-reported health care utilization.  
4.4 Aim III: Examine relationships between child psychological variables, caregiver 
psychological variables, family functioning, and pain outcomes 
 Table 4.16 provides correlation results for the association of child age and gender, 
and child, caregiver, and family variables. Table 4.17 provides correlations results for the 
association of caregiver and family variables with pain outcomes. Age and gender were 
examined to determine their potential use as covariates in future studies. 
 Age and Gender, Caregiver Psychological Variables, and Family 
Functioning. Age was significantly related to caregiver negative mood, with older child 
age related to higher caregiver negative mood. Gender was significantly related to family 
functioning, such that girls had poorer ratings of family functioning versus boys. 
 Trends. Trends were observed between age and caregiver positive mood and 
family functioning, with older child age related to lower caregiver positive mood and 
poorer family functioning. 
 Child and Caregiver Psychological Variables and Family Functioning. Child 
negative thinking was significantly associated with family functioning, with higher child 
negative thinking associated with poorer family functioning. This result provides support 
for hypothesis 6, specific to child negative thinking. 
 Trends. A trend was observed between child negative thinking and caregiver 
passive coping and negative mood, such that higher child negative thinking was related to 
higher caregiver passive coping and negative mood. In addition, a trend was found for 
child positive mood and caregiver active coping and positive mood, with higher child 
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positive mood associated with higher caregiver active coping and positive mood. These 
results provide preliminary support for hypothesis 5 specific to caregiver passive coping 
and positive mood, which directly mirrored similar constructs in children. 
 Caregiver Psychological Variables, Family Functioning, and Pain Outcomes. 
For health care utilization, caregiver passive coping was significantly related to medical 
record health care utilization, with higher passive coping associated with higher health 
care utilization. Caregiver negative mood was also significantly medical record health 
care utilization, with higher caregiver negative mood associated with health care 
utilization. These findings provide support for hypothesis 7, specific to caregiver passive 
coping and negative mood. Additional exploratory analyses with other pain features 
suggested that caregiver negative mood was significantly related to pain duration, with 
higher negative mood associated with longer pain duration. 
 Trends. A trend was observed between caregiver active coping and medical 
record health care utilization, with higher active coping associated with higher health 
care utilization. In addition, a trend was observed for caregiver passive coping and 
caregiver- and child-reported health care utilization, with higher passive coping 
associated with higher health care utilization. The latter result provides additional support 
for hypothesis 7. Additional exploratory analyses with other pain features suggested that 
caregiver passive coping was also associated with pain duration, with higher caregiver 
passive coping associated with longer pain duration.  
 Results Summary: Future Mediation Analysis.  The above relationships were 
compared to the original relationships from Table 4.1 for child psychological variables 
and pain outcomes for the full sample. The most probable relationships in support of 
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future mediation were for child negative thinking as a mediator of caregiver passive 
coping and negative mood in predicting health care utilization (as measured by the 
medical record). These relationships are depicted in Figure 4.9. Using Fritz and 
Mackinnon (2007), a sample size was estimated to detect the mediated effect. This 
reference suggested that 148 to 196 participants would be needed to detect the mediated 
effect, depending on the statistical method used. 
 Supplemental Analysis: Direct Effects of Caregiver Variables on Pain 
Outcomes. Although the primary analyses were focused on uncovering possible 
mediation or indirect effects of caregiver variables, it is also possible that caregiver 
variables had direct effects on pain outcomes. Thus, a supplemental analysis was 
conducted to determine whether caregiver variables had direct effects on pain outcomes 
after controlling for biological and child psychological variables. Three models were 
chosen, one for pain duration and one for each of the health care utilization variables. For 
child and caregiver psychological variables, only those variables demonstrating a 
correlation of ≥ .20 were chosen. In addition, due to the large correlation between 
caregiver passive coping and caregiver negative mood, only one variable was chosen for 
the final models to avoid issues of multicollinearity. The variable with the higher 
correlation was chosen in these circumstances.  
 Results for the supplemental analysis can be found in Table 4.18. For pain 
duration, the overall regression model was significant, F (3, 65) = 2.83, p = .045, with the 
model explaining 12% of the variance overall. Above and beyond sickle cell risk group 
and child positive mood, the addition of caregiver negative mood accounted for a 
significant amount of variance, ∆F (1, 65) = 5.35, p = .024, ∆R2 = .07. According to the 
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unstandardized beta coefficient, for every one-point change in caregiver negative mood, 
there was a .68 increase in pain duration. For caregiver- and child-reported health care 
utilization, the overall regression model was significant, F (4, 64) = 4.59, p = .003, with 
the model explaining 22% of the variance overall. Above and beyond sickle cell risk 
group and child psychological variables, caregiver passive coping did not contribute a 
significant amount of variance to the model, ∆F (1, 64) = 2.24, p = .140, ∆R2 = .03. 
Finally, for the model for medical record health care utilization, the overall regression 
model was significant, F (5, 63) = 4.25, p = .002, with the model explaining 25% of the 
variance overall. Above and beyond sickle cell risk group and child psychological 
variables, the addition of caregiver active and passive coping accounted for a significant 
amount of variance, ∆F (2, 63) = 4.33, p = .017, ∆R2 = .10. There were trends for 
caregiver active, t (1, 68) = 1.80, p = .076, and passive coping, t (1, 68) = 1.71, p = .092, 
as individual predictors of health care utilization. 
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Table 4.1. 
Full Sample: Correlations between Covariates, Predictors, and Pain Outcomes 
 
†p  <  .10  *p  <  .05  **p  <  .01  ***p  <  .001  HC = Health Care
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 
1. Age -            
2. Gender .13 -           
3. Sickle Cell  
Risk Group 
.19 -.24* -          
4. Coping Attempts -.25* -.07 -.03 -         
5. Negative Thinking .14 -.26* .28* .25* -        
6. Positive Mood -.16 -.06 .07 .36** -.13 -       
7. Negative Mood -.02 -.26* -.02 .31** .42*** -.21† -      
8. Pain Rate .01 -.02 .00 .11 .32** -.21† .13 -     
9. Pain Intensity .11 -.11 .25* .03 .21† -.01 .03 -.02 -    
10. Pain Duration .03 .03 -.01 -.14 .13 -.20† .14 .08 .15 -   
11. HC Utilization 
(Caregiver and Child) 
.08 -.13 .14 -.04 .22† -.25* .15 .53*** .24* .18 -  
12. HC Utilization  
(Medical Record) 
.15 .07 .23* -.11 .25* -.25* .11 .38** .25* .14 .67*** - 
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Table 4.2. 
Full Sample: Multiple Hierarchical Regressions Predicting Pain Rate, Intensity, and 
Duration 
 
Note. Pain rate was log-transformed to generate the final results. The original untransformed 
unstandardized beta coefficients and standard errors are presented alongside the final values. The 
untransformed values are first, followed by the log-transformed values. Values are separated by a slash.  
†p  <  .10  *p  <  .05  
  
Variable B B SE β ∆R2 Total R2 
Outcome: Pain Rate      
Demographics 
    Age 
    Gender 
 
.03/.01 
-.50/-.12 
 
.46/.02 
2.96/.11 
 
.03 
-.13 
.02 
 
.02 
 
Biological Variable 
    Sickle Cell Risk Group 
 
-.44/.15 
 
3.31/.12 
 
.15 
.02 .04 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
.05/.00 
.16/.01† 
-3.01/-.15* 
-1.95/-.04 
 
.06/.00 
.07/.00 
1.77/.06 
2.92/.11 
 
.13 
.26 
-.30 
-.06 
.16* .20 
Outcome: Pain Intensity      
Demographics 
    Age 
    Gender 
 
.09 
-.55 
 
.06 
.39 
 
.18 
-.16 
.05 .05 
Biological Variable 
    Sickle Cell Risk Group 
 
.89* 
 
.43 
 
.25 
.06* .10 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
.00 
.01 
-.03 
-.21 
 
.01 
.01 
.25 
.41 
 
.05 
.15 
-.02 
-.07 
.02 .13 
Outcome: Pain Duration      
Demographics 
    Age 
    Gender 
 
.02 
.09 
 
.07 
.44 
 
.03 
.02 
.00 .00 
Biological Variable 
    Sickle Cell Risk Group 
 
-.04 
 
.50 
 
-.01 
.00 .00 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
-.01 
.01 
-.14 
.49 
 
.01 
.01 
.28 
.46 
 
-.21 
.15 
-.07 
.15 
.09 .09 
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Table 4.3. 
Full Sample: Multiple Hierarchical Regressions Predicting Health Care Utilization 
Outcomes 
 
 
Note. Caregiver- and child-reported health care utilization was log-transformed to generate the final results. 
The original untransformed unstandardized beta coefficients and standard errors are presented alongside the 
final values. The untransformed values are first, followed by the log-transformed values. Values are 
separated by a slash.  
†p  <  .10  *p  <  .05 
Variable B B SE β ∆R2 Total R2 
Outcome: Health Care Utilization 
(Caregiver and Child Report)  
     
Demographics 
    Age 
    Gender 
 
.30/.02 
-2.70/-.14 
 
.34/.02 
2.18/.11 
 
.14 
-.15 
.04 
 
.04 
 
Biological Variable 
    Sickle Cell Risk Group 
 
1.91/.19 
 
2.43/.12 
 
.18 
.03 .07 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
.01/.00 
.04/.00 
-2.45/-.15* 
.33/.05 
 
.04/.00 
.05/.00 
1.35/.07 
2.23/.11 
 
-.02 
.13 
-.30 
.06 
.13* .20 
Outcome: Health Care Utilization 
(Medical Record) 
     
Demographics 
    Age 
    Gender 
 
.15 
.54 
 
.15 
.95 
 
.12 
.07 
.02 .02 
Biological Variable 
    Sickle Cell Risk Group 
 
1.98† 
 
1.04 
 
.23 
.05† .07 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
-.01 
.03 
-.73 
.53 
 
.02 
.02 
.57 
.94 
 
-.11 
.21 
-.17 
.08 
.10† .17 
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Table 4.4. 
Sickle Cell Anemia and Sickle Cell Beta-0-Thalassemia Subtypes: Correlations between Covariates, Predictors, and Pain Outcomes 
 
†p  <  .10  *p  <  .05  **p  <  .01  ***p  <  .001  HC = Health Care
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 
1. Age -                
2. Gender .18 -               
3. Hematocrit -.04 -.16 -              
4. Fetal Hemoglobin -.19 -.30* .58*** -             
5. White Blood Cells -.14 -.02 -.35* -.45** -            
6. Platelets -.03 .01 .00 -.07 .01 -           
7. Alpha Thalassemia -.03 .11 .04 -.19 .32* -.21 -          
8. Coping Attempts -.31* -.04 .13 .24† .06 .06 .05 -         
9. Negative Thinking .02 -.11 .01 .05 .18 -.04 .23 .26† -        
10. Positive Mood -.19 -.07 .09 .18 -.20 -.25† .11 .34* -.07 -       
11. Negative Mood -.12 -.27† .06 .19 .19 .14 .10 .33* .36** -.08 -      
12. Pain Rate .05 .05 .05 .05 .01 -.08 .31* .09 .30* -.11 .11 -     
13. Pain Intensity .00 -.02 .09 
 
-.15 .03 .21 -.03 .02 .07 -.07 .01 -.14 -    
14. Pain Duration -.08 .04 .06 -.20 .18 .08 .13 -.16 .04 -.05 -.04 .11 .18 -   
15. HC Utilization 
(Caregiver and Child) 
.12 -.10 .13 .02 -.08 .09 -.02 -.05 .13 -.20 .16 .40* .22 .26† -  
16. HC Utilization 
(Medical Record) 
.22 .22 .04 -.02 -.11 .13 .06 -.21 .23 -.37** .11 .27* .21 .29* .62*** - 
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Table 4.5. 
Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Multiple Hierarchical Regressions 
Predicting Pain Rate and Intensity 
 
 
Note. Pain rate was log-transformed to generate the final results. The original untransformed 
unstandardized beta coefficients and standard errors are presented alongside the final values. The 
untransformed values are first, followed by the log-transformed values. Values are separated by a slash.  
†p  <  .10   
 
 
  
Variable B B SE β ∆R2 Total R2 
Outcome: Pain Rate      
Demographics 
    Age 
    Gender 
 
.15/-.01 
1.00/.00 
 
.57/.02 
3.51/.12 
 
-.04 
.00 
.00 
 
.00 
 
Biological Covariate 
    Alpha thalassemia 
 
10.25/.24 
 
4.54/.16 
 
.21 
.05 .05 
Biological Variables 
    Hematocrit 
    Fetal hemoglobin 
 
-.17/.03 
.21/.00 
 
.58/.02 
.23/.01 
 
.22 
-.03 
.04 .09 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
.03/.00 
.10/.00 
-2.50/-.12 
-.94/.05 
 
.07/.00 
.08/.00 
2.27/.08 
3.32/.11 
 
.00 
.17 
-.25 
.08 
.11 .20 
Outcome: Pain Intensity      
Demographics 
    Age 
    Gender 
 
-.02 
.03 
 
.08 
.48 
 
-.04 
.01 
.00 .00 
Biological Covariate 
    Platelet count 
 
.00 
 
.00 
 
.23 
.05 .06 
Biological Variables 
    Hematocrit 
    Fetal hemoglobin 
 
.12 
-.05† 
 
.08 
.03 
 
.26 
-.31 
.07 .12 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
.00 
.00 
-.06 
-.08 
 
.01 
.01 
.33 
.47 
 
.03 
.06 
-.03 
-.03 
.01 .13 
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Table 4.6. 
Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Multiple Hierarchical Regressions 
Predicting Pain Duration 
 
 
†p  <  .10  *p  <  .05   
 
  
Variable B B SE β ∆R2 Total R2 
Outcome: Pain Duration      
Demographics 
    Age 
    Gender 
 
-.05 
.19 
 
.08 
.47 
 
-.09 
.06 
.01 
 
.01 
 
Biological Variables 
    Hematocrit 
    Fetal hemoglobin 
 
.13† 
-.07* 
 
.08 
.03 
 
.29 
-.40 
.10† .11 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
-.01 
.01 
.07 
.07 
 
.01 
.01 
.30 
.45 
 
-.22 
.11 
.04 
.03 
.04 .15 
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Table 4.7. 
Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Multiple Hierarchical Regressions 
Predicting Health Care Utilization Outcomes 
 
 
Note. Caregiver- and child-reported health care utilization was log-transformed to generate the final results. 
The original untransformed unstandardized beta coefficients and standard errors are presented alongside the 
final values. The untransformed values are first, followed by the log-transformed values. Values are 
separated by a slash. 
†p  <  .10  *p  <  .05   
 
  
Variable B B SE β ∆R2 Total 
R2 
Outcome: Health Care Utilization 
(Caregiver and Child Report)  
     
Demographics 
    Age 
    Gender 
 
.28/.01 
-1.60/.00 
 
.44/.02 
2.73/.13 
 
.06 
.00 
.00 
 
.00 
 
Biological Variables 
    Hematocrit 
    Fetal hemoglobin 
 
.45/.03 
-.08/-.01 
 
.46/.02 
.18/.01 
 
.26 
-.19 
.05 .05 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
-.01/.00 
.01/.00 
-2.29/-.14† 
2.14/.16 
 
.06/.00 
.06/.00 
1.81/.08 
2.68/.12 
 
-.17 
.00 
-.27 
.21 
.15 .20 
Outcome: Health Care Utilization 
(Medical Record)  
     
Demographics 
    Age 
    Gender 
 
.18 
1.84 
 
.18 
1.13 
 
.14 
.23 
.09 
 
.09 
 
Biological Variables 
    Hematocrit 
    Fetal hemoglobin 
 
.06 
.02 
 
.19 
.08 
 
.05 
.06 
.01 .10 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
    Negative Mood 
 
-.03 
.04 
-1.42* 
.98 
 
.02 
.02 
.68 
1.01 
 
-.23 
.21 
-.30 
.15 
.23* .32 
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Table 4.8. 
Supplemental Analysis for the Full Sample: Pre-Hydroxyurea Correlations between 
Sickle Cell Risk Group and Multiple Pain Outcomes 
 
 
†p  <  .10  *p  <  .05  **p  <  .01  ***p  <  .001    
Variable 1. 2. 3. 4. 5. 6. 
1. Sickle Cell Risk Group -      
2. Pain Rate .16 -     
3. Pain Intensity .33** 
 
.05 -    
4. Pain Duration .03 .01 .21† -   
5. Health Care Utilization 
(Caregiver and Child) 
.25* .49*** .44*** .19† -  
6. Health Care Utilization 
(Medical Record 
.25* .59*** .20† .10 .38** - 
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Table 4.9. 
Supplemental Analysis for Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Pre-
Hydroxyurea Hematocrit and Fetal Hemoglobin Predicting Multiple Pain Outcomes 
 
 
†p  <  .10  *p  <  .05
Variable B B SE β Total R2 
Outcome: Pain Rate      
Hematocrit 
Fetal Hemoglobin 
-1.06 
.27 
.87 
.32 
-.22 
.15 
.04 
Outcome: Pain Intensity      
Hematocrit 
Fetal Hemoglobin 
-.18 
.11* 
.11 
.04 
-.27 
.44 
.14* 
Outcome: Pain Duration      
Hematocrit 
Fetal Hemoglobin 
.25† 
-.07 
.13 
.05 
.34 
-.27 
.09 
Outcome: Health Care Utilization 
(Caregiver and Child Report)  
    
Hematocrit 
Fetal Hemoglobin 
-1.11 
.50 
1.11 
.40 
-.18 
.22 
.04 
Outcome: Health Care Utilization 
(Medical Record)  
    
Hematocrit 
Fetal Hemoglobin 
.31† 
-.03 
.18 
.06 
.30 
-.08 
.07 
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Table 4.10. 
Full Sample: Multiple Hierarchical Regressions Predicting Pain Rate and Duration with 
Interactions 
 
 
Note. Pain rate was log-transformed to generate the final results. The original untransformed 
unstandardized beta coefficients and standard errors are presented alongside the final values. The 
untransformed values are first, followed by the log-transformed values. Values are separated by a slash.  
†p  <  .10  *p  <  .05  **p  <  .01  SC = sickle cell  
 
 
 
 
 
 
 
 
 
 
Variable B B SE β ∆R2 Total 
R2 
Outcome: Pain Rate      
Biological Variable 
    Sickle Cell Risk Group 
 
-.13/.08 
 
1.56/.06 
 
.17 
.03 .03 
Psychological Variables 
    Negative Thinking 
    Positive Mood 
 
.15/.01* 
-2.09/-.11* 
 
.06/.00 
1.49/.05 
 
.29 
-.23 
.15** .18 
Interactions 
    SC Risk Group x Negative Thinking 
    SC Risk Group x Positive Mood 
 
.01/.00 
1.16/.02 
 
.06/.00 
1.52/.06 
 
-.06 
.04 
.01 .18 
Outcome: Pain Duration      
Biological Variable 
    Sickle Cell Risk Group 
 
-.02 
 
.23 
 
-.01 
.00 .00 
Psychological Variable 
    Positive Mood 
 
-.39† 
 
.23 
 
-.20 
.04† .04 
Interaction 
    SCD Risk Group x Positive Mood 
 
.35 
 
.23 
 
.18 
.03 .07 
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Table 4.11. 
Full Sample: Multiple Hierarchical Regressions Predicting Health Care Utilization 
Outcomes with Interactions 
 
 
Note. Caregiver- and child-reported health care utilization was log-transformed to generate the final results. 
The original untransformed unstandardized beta coefficients and standard errors are presented alongside the 
final values. The untransformed values are first, followed by the log-transformed values. Values are 
separated by a slash. 
†p  <  .10  *p  <  .05  **p  <  .01  SCD = sickle cell disease 
Variable B B SE β ∆R2 Total 
R2 
Outcome: Health Care Utilization 
(Caregiver and Child Report)  
     
Biological Variable 
    Sickle Cell Risk Group 
 
1.36/.11* 
 
1.15/.06 
 
.22 
.05* .05 
Psychological Variables 
    Negative Thinking 
    Positive Mood 
 
.06/.00 
-2.37/-.16** 
 
.04/.00 
1.13/.06 
 
.17 
-.32 
.14** .19 
Interactions 
    SCD Risk Group x Negative Thinking 
    SCD Risk Group x Positive Mood 
 
-.02/.00 
.21/-.02 
 
.05/.00 
1.18/.06 
 
-.19 
-.03 
.03 .22 
Outcome: Health Care Utilization 
(Medical Record) 
     
Biological Variable 
    Sickle Cell Risk Group 
 
.92† 
 
.50 
 
.21 
.05† .05 
Psychological Variables 
    Negative Thinking 
    Positive Mood 
 
.03 
-1.04* 
 
.02 
.49 
 
.16 
-.24 
.09* .14 
Interactions 
    SCD Risk Group x Negative Thinking 
    SCD Risk Group x Positive Mood 
 
.01 
-.78 
 
.02 
.50 
 
.06 
-.18 
.04 .18 
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Table 4.12. 
Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Multiple Hierarchical Regression 
Predicting Pain Rate with Interactions 
 
 
Note. Pain rate was log-transformed to generate the final results. The original untransformed 
unstandardized beta coefficients and standard errors are presented alongside the final values. The 
untransformed values are first, followed by the log-transformed values. Values are separated by a slash.   
Hct = hematocrit  Fet Hgb = fetal hemoglobin 
 
 
  
Variable B B SE β ∆R2 Total 
R2 
Outcome: Pain Rate      
Biological Covariate 
    Alpha thalassemia 
 
10.24/.23 
 
4.43/.15 
 
.21 
.05 .05 
Biological Variables 
    Hematocrit 
    Fetal hemoglobin 
 
-.14/.02 
.17/.00 
 
.57/.02 
.22/.01 
 
.22 
-.03 
.04 .09 
Psychological Variables 
   Negative Thinking 
 
.12/.00 
 
.07/.00 
 
.23 
.05 .14 
Interactions 
    Hct x Negative Thinking 
    FetHgb x Negative Thinking 
 
-.06/.00 
.01/.00 
 
.03/.00 
.01/.00 
 
-.08 
.02 
.00 .14 
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Table 4.13. 
Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Multiple Hierarchical Regressions 
Predicting Health Care Utilization Outcomes with Interactions 
 
 
Note. Caregiver- and child-reported health care utilization was log-transformed to generate the final results. 
The original untransformed unstandardized beta coefficients and standard errors are presented alongside the 
final values. The untransformed values are first, followed by the log-transformed values. Values are 
separated by a slash. 
†p  <  .10  *p  <  .05  Hct = hematocrit  FetHgb = fetal hemoglobin 
Variable B B SE β ∆R2 Total 
R2 
Outcome: Health Care Utilization 
(Caregiver and Child Report)  
     
Biological Variables 
    Hematocrit 
    Fetal hemoglobin 
 
.46/.03 
-.08/-.01 
 
.45/.02 
.17/.01 
 
.27 
-.20 
.05 .05 
Psychological Variables 
    Positive Mood 
 
-2.67/-.18* 
 
1.57/.07 
 
-.34 
.11* .16 
Interactions 
    Hct x Positive Mood 
    Fet Hgb x Positive Mood 
 
.85/.02 
.06/.01 
 
.70/.03 
.22/.01 
 
.16 
.13 
.05 .21 
Outcome: Health Care Utilization 
(Medical Record)  
     
Demographics 
    Age 
    Gender 
 
.18 
1.84 
 
.18 
1.13 
 
.14 
.23 
.09 
 
.09 
 
Biological Variables 
    Hematocrit 
    Fetal hemoglobin 
 
.06 
.02 
 
.19 
.08 
 
.05 
.06 
.01 .09 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
 
-.02 
.04† 
-1.55* 
 
.02 
.02 
.67 
 
-.18 
.25 
-.33 
.21* .30 
Interactions 
    Hct x Coping Attempts 
    FetHgb x Coping Attempts 
    Hct x Negative Thinking 
    FetHgb x Negative Thinking 
    Hct x Positive Mood 
    FetHgb x Positive Mood 
 
.00 
.00 
.00 
.00 
.64† 
-.08 
 
.01 
.00 
.01 
.00 
.33 
.10 
 
.05 
-.01 
.06 
.00 
.53 
-.18 
.10 .41 
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Table 4.14. 
Supplemental Analysis for Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: 
Multiple Hierarchical Regressions Predicting Pain Rate and Health Care Utilization 
Outcomes (Hematocrit only) 
 
Note. Pain rate and caregiver- and child-reported health care utilization were log-transformed to generate 
the final results. The original untransformed unstandardized beta coefficients and standard errors are 
presented alongside the final values. The untransformed values are first, followed by the log-transformed 
values. Values are separated by a slash. †p  <  .10  *p  <  .05  Hct = hematocrit   
  
Variable B B SE β ∆R2 Total R2 
Outcome: Pain Rate      
Biological Covariate 
    Alpha thalassemia 
 
10.19/.23 
 
4.38/.15 
 
.21 
.04 .04 
Biological Variables 
    Hematocrit 
 
.13/.02 
 
.45/.02 
 
.20 
.04 .08 
Psychological Variables 
   Negative Thinking 
 
.12/.00† 
 
.07/.00 
 
.23 
.05 .14† 
Interactions 
    Hct x Negative Thinking 
 
-.05/.00 
 
.02/.00 
 
-.06 
.00 .14 
Outcome: Health Care Utilization 
(Caregiver and Child Report)  
     
Biological Variables 
    Hematocrit 
 
.35/.02 
 
.37/.02 
 
.15 
.02 .02 
Psychological Variables 
    Positive Mood 
 
-2.38/-.18* 
 
1.57/.07 
 
-.32 
.10 .13* 
Interactions 
    Hct x Positive Mood 
 
.99/.04 
 
.50/.02 
 
.26 
.04 .17 
Outcome: Health Care Utilization 
(Medical Record)  
     
Demographics 
    Age 
    Gender 
 
.25 
1.53 
 
.18 
1.13 
 
.19 
.19 
.08 
 
.08 
 
Biological Variables 
    Hematocrit 
 
.09 
 
.16 
 
.08 
.01 .09 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
 
-.02 
.05* 
-1.31† 
 
.02 
.02 
.67 
 
-.18 
.28 
-.27 
.18* .28 
Interactions 
    Hct x Coping Attempts 
    Hct x Negative Thinking 
    Hct x Positive Mood 
 
.00 
.00 
.44† 
 
.01 
.01 
.23 
 
.01 
.06 
.36 
.08 .36 
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Table 4.15. 
Supplemental Analysis for Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: 
Multiple Hierarchical Regressions Predicting Pain Rate and Health Care Utilization 
Outcomes (Fetal Hemoglobin only) 
 
 
Note. Pain rate and caregiver- and child-reported health care utilization were log-transformed to generate 
the final results. The original untransformed unstandardized beta coefficients and standard errors are 
presented alongside the final values. The untransformed values are first, followed by the log-transformed 
values. Values are separated by a slash. †p  <  .10  *p  <  .05  FetHgb = fetal hemoglobin 
 
Variable B B SE β ∆R2 Total R2 
Outcome: Pain Rate      
Biological Covariate 
    Alpha thalassemia 
 
10.24/.23 
 
4.43/.15 
 
.21 
.05 .05 
Biological Variables 
    Fetal Hemoglobin 
 
.14/.00 
 
.17/.01 
 
.11 
.01 .06 
Psychological Variables 
   Negative Thinking 
 
.12/.00 
 
.07/.00 
 
.21 
.04 .10 
Interactions 
    FetHgb x Negative Thinking 
 
.00/.00 
 
.01/.00 
 
-.02 
.00 .10 
Outcome: Health Care Utilization 
(Caregiver and Child Report)  
     
Biological Variables 
    Fetal Hemoglobin 
 
.02/.00 
 
.14/.01 
 
-.04 
.00 .00 
Psychological Variables 
    Positive Mood 
 
-2.71/-.18* 
 
1.57/.07 
 
-.34 
.12* .12 
Interactions 
    FetHgb x Positive Mood 
 
.26/.01† 
 
.15/.01 
 
.23 
.05† .17 
Outcome: Health Care Utilization 
(Medical Record)  
     
Demographics 
    Age 
    Gender 
 
.18 
1.84 
 
.18 
1.13 
 
.14 
.23 
.09 
 
.09 
 
Biological Variables 
    Fetal Hemoglobin 
 
.04 
 
.06 
 
.09 
.01 .09 
Psychological Variables 
    Coping Attempts 
    Negative Thinking 
    Positive Mood 
 
-.02 
.04† 
-1.56* 
 
.02 
.02 
.66 
 
-.18 
.25 
-.33 
.21* .30 
Interactions 
    FetHgb x Coping Attempts 
    FetHgb x Negative Thinking 
    FetHgb x Positive Mood 
 
.00 
.01 
.06 
 
.00 
.00 
.07 
 
.03 
.08 
.13 
.03 .33 
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Table 4.16. 
Correlations between Child and Caregiver Psychological and Family Variables 
 
 
†p  <  .10  *p  <  .05  **p  <  .01  ***p  <  .001 
  
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. Age -           
2. Gender .13 -          
3. Child Coping Attempts -.25* 
 
-.07 -         
4. Child Negative Thinking .14 -.26* .25* -        
5. Child Positive Mood -.16 -.06 .36** -.13 -       
6. Child Negative Mood -.02 -.26* .31** .42*** -.21† -      
7. Caregiver Active Coping -.12 .19 .17 .07 .22† -.01 -     
8. Caregiver Passive Coping .17 .02 .03 .21† -.10 .05 .27* -    
9. Caregiver Positive Mood -.23† .14 .03 -.16 .21† -.08 .19 -.20† -   
10. Caregiver Negative Mood .32** .08 -.06 .23† -.19 .06 .02 .62*** -.49*** -  
11. Family Functioning .21† -.27* -.03 .26* -.10 .07 -.11 .27* -.58*** .32** - 
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Table 4.17. 
Correlations between Caregiver Psychological and Family Variables and Child Pain Outcomes 
 
 
†p  <  .10  *p  <  .05  **p  <  .01  ***p  <  .001   
 
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
1. Caregiver Active Coping -          
2. Caregiver Passive Coping .27* -         
3. Caregiver Positive Mood .19 -.20† -        
4. Caregiver Negative Mood .02 .62*** -.49*** -       
5. Family Functioning -.11 .27* -.58*** .32** -      
6. Child Pain Rate .15 .16 -.12 .05 .03 -     
7. Child Pain Intensity .04 -.07 .05 .02 .04 .15 -    
8. Child Pain Duration -.07 .20† -.06 .28* .01 .11 .15 -   
9. Child Health Care Utilization 
(Caregiver and Child Report) 
.11 .22† -.12 .05 -.02 .74*** .24* .18 -  
10. Child Health Care Utilization 
(Medical Record) 
.21† .31** .04 .25* -.09 .48*** .25* .14 .67*** - 
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Table 4.18. 
Supplemental Analysis: Direct Effects of Biological and Child and Caregiver 
Psychological Variables in Relation to Pain Duration and Health Care Utilization 
 
 
Note. Caregiver- and child-reported health care utilization was log-transformed to generate the final results. 
The original untransformed unstandardized beta coefficients and standard errors are presented alongside the 
final values. The untransformed values are first, followed by the log-transformed values. Values are 
separated by a slash.  
†p  <  .10  *p  <  .05  **p  <  .01  
Variable B B SE β ∆R2 Total R2 
Outcome: Pain Duration      
Biological Variables 
    Sickle Cell Risk Group 
 
.51 
 
.45 
 
.14 
.02 .02 
Child Psychological Variables 
    Positive Mood 
 
-.29 
 
.22 
 
-.15 
.02 .04 
Caregiver Psychological Variable 
    Negative Mood 
 
.68* 
 
.29 
 
.28 
.07* .12 
Outcome: Health Care Utilization 
(Caregiver and Child Report) 
     
Biological Variable 
    Sickle Cell Risk Group 
 
1.53/.12* 
 
1.24/.06 
 
.24 
.06* .06 
Child Psychological Variables 
    Negative Thinking 
    Positive Mood 
 
.06/.00 
-2.46/-.16** 
 
.04/.00 
1.21/.06 
 
.18 
-.31 
.14** .20 
Caregiver Psychological Variable 
    Passive Coping 
 
.21/.01 
 
.14/.01 
 
.17 
.03 .22 
Outcome: Health Care Utilization 
(Medical Record) 
     
Biological Variable 
    Sickle Cell Risk Group 
 
1.69 
 
1.07 
 
.19 
.04 .04 
Child Psychological Variables 
    Negative Thinking 
    Positive Mood 
 
.03 
-1.22* 
 
.02 
.52 
 
.17 
-.27 
.11* .15 
Caregiver Psychological 
Variables 
    Active Coping 
    Passive Coping 
 
.05† 
.10† 
 
.03 
.06 
 
.21 
.20 
.10* .25 
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Figure 4.1. The relationship between positive mood and pain duration is dependent on 
sickle cell risk group. Children with low-risk subtypes demonstrated a stronger, negative 
relationship between positive mood and pain duration while this relationship was 
relatively weaker for children with high-risk subtypes. 
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Figure 4.2. The relationship between negative thinking and caregiver- and child-reported 
health care utilization is dependent on sickle cell risk group. Children with low-risk 
subtypes demonstrated a stronger, positive relationship between negative thinking and 
health care utilization over the previous 12 months as measured by caregiver and child 
report. This relationship was relatively weaker for children with high-risk subtypes. 
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Figure 4.3. The relationship between positive mood and caregiver- and child-reported 
health care utilization is dependent on sickle cell risk group. Children with low-risk 
subtypes demonstrated a stronger, negative relationship between positive mood and 
health care utilization over the previous 12 months as measured by caregiver and child 
report. This relationship was relatively weaker for children with high-risk subtypes. 
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Figure 4.4. The relationship between negative thinking and medical record health care 
utilization is dependent on sickle cell risk group. Children with high-risk subtypes 
demonstrated a stronger, positive relationship between negative thinking and health care 
utilization over the previous 24 months as measured by the medical record. This 
relationship was relatively weaker for children with low-risk subtypes. 
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Figure 4.5. The relationship between positive mood and medical record health care 
utilization is dependent on sickle cell risk group. Children with high-risk subtypes 
demonstrated a stronger, negative relationship between positive mood and health care 
utilization over the previous 24 months as measured by the medical record. This 
relationship was relatively weaker for children with low-risk subtypes. 
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Figure 4.6. The relationship between positive mood and caregiver- and child-reported 
health care utilization is dependent on hematocrit. Children with lower hematocrit 
demonstrated a stronger, negative relationship between positive mood and health care 
utilization over the previous 12 months as measured by caregiver and child report. This 
relationship was relatively weaker for children with higher hematocrit.  
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Figure 4.7. The relationship between positive mood and caregiver- and child-reported 
health care utilization is dependent on fetal hemoglobin. Children with lower fetal 
hemoglobin demonstrated a stronger, negative relationship between positive mood and 
health care utilization over the previous 12 months as measured by caregiver and child 
report. This relationship was relatively weaker for children with higher fetal hemoglobin. 
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Figure 4.8. The relationship between positive mood and medical record health care 
utilization is dependent on hematocrit. Children with lower hematocrit demonstrated a 
stronger, negative relationship between positive mood and health care utilization over the 
previous 24 months as measured by the medical record. This relationship was relatively 
weaker for children with higher hematocrit.  
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Figure 4.9. Proposed mediation model for future studies assessing child psychological 
variables as mediators of caregiver psychological variables and health care utilization. 
The proposed model, based on correlations results, suggests that the effects of caregiver 
passive coping and negative mood may be mediated by child negative thinking in 
predicting health care utilization for pain. 
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CHAPTER 5 
STUDY TWO RESULTS 
 Study Two examined a novel genetic marker of pain in pediatric SCD. As with 
Study One, the primary results are described below followed by supplemental analyses 
designed to complement or address key limitations of the original analysis.  
5.1 Allele Distributions  
 In both the full sample and subsample of children with HbSS and HbSβ0, the 
distribution for the A allele was .45 and for the G allele was .55. These allele frequencies 
were in accordance with Hardi-Weinberg equilibrium, χ2 (1) = 0.74, p > .05. The allele 
frequencies observed were also comparable to those found in a large sample of African 
Americans listed in the National Institutes of Health SNP database (.44 for A allele and 
.56 for G allele; N = 122). 
5.2 Regression Assumptions 
 Similar to the analysis for Study One, the two primary issues identified for 
regression assumptions in Study Two were non-normality of residuals and the presence 
of influential cases for pain rate and caregiver- and child-reported health care utilization. 
Thus, the same modifications were made to the data, including log-transformation of 
these outcome variables and presentation of the results using both the original, 
untransformed and log-transformed beta coefficients. Independence of errors was 
assumed for the models, as the Durbin-Watson statistic did not exceed lower limits for 
this statistic (Durbin-Watson ranged from 1.61 to 2.25). Multicollinearity for the two
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coefficients representing genotype comparisons was expected and no other correlations 
between the covariates and primary predictors exceeded .50; thus, this assumption was 
assumed to be adequate. No curvilinear patterns or systematic deviations from 
homoscedasticity were identified on residual plots. 
5.3 Primary Aim Results 
 Full Sample. Table 5.1 provides biserial correlations to demonstrate relationships 
between the ET-B genotypes and pain features for the full sample. Table 5.2 provides 
means and standard deviations by genotype for each pain outcome to aid in interpretation. 
Neither age nor gender had a correlation of .20 or higher with any pain outcomes; thus, 
correlations between the ET-B genotypes and pain features were used in lieu of linear 
regression. The correlations between ET-B genotypes and caregiver- and child-reported 
health care utilization were not significant. For medical record health care utilization, the 
correlation comparing the A/G versus the A/A genotypes approached significance (r = 
.22, p = .065); however, the correlation comparing the G/G and A/A genotypes was not 
significant nor was it in the expected direction (r = -.15, p = .194). Thus, hypothesis 8 
regarding the association of ET-B genotype and health care utilization was not supported 
for either health care utilization outcome.  
 In terms of additional pain features, the correlation comparing the A/G versus the 
A/A genotype was significant for pain duration (r = .27, p = .022); however, the 
correlation comparing the G/G and A/A genotypes was not significant nor was it in the 
expected direction (r = -.11, p = .345).  Cumulatively, these results do not lend consistent 
support for the G allele conferring greater risk than the A allele.  
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 Sickle Cell Anemia and Sickle Cell Beta-0-Thalassemia. Table 5.3 provides 
biserial correlations to demonstrate the relationships between the ET-B genotypes and 
pain features for the subsample of children with HbSS and HbSβ0. Table 5.5 provides 
means and standard deviations by genotype for each pain outcome to aid in interpretation. 
There were no covariates for caregiver- and child-reported health care utilization that 
demonstrated correlations ≥ .20, and neither of the correlations with the ET-B genotypes 
was significant. For medical record health care utilization, age and gender were entered 
into a linear regression model with both of the ET-B coefficients (Table 5.4). The overall 
regression model was not significant, F (4, 45) = 1.28, p = .292, with the model 
accounting for 10% of the variance overall. After controlling for age and gender, the ET-
B coefficients did not contribute a significant amount of variance to the model, ∆F (2, 45) 
= 0.49, p = .614, ∆R2 = .02. Thus, similar to the full sample, hypothesis 8 was not 
supported for health care utilization. 
 Exploratory models were examined for additional pain features. For pain rate, 
alpha thalassemia trait was entered as a covariate with the ET-B genotypes. The overall 
regression model was not significant, F (3, 46) = 0.43, p = .733, with the model 
explaining 3% of the variance overall. After controlling for alpha thalassemia trait, the 
ET-B coefficients did not contribute a significant amount of variance to the model, ∆F (2, 
46) = 0.58, p = .563, ∆R2 = .02. For pain intensity, platelet count was entered as a 
covariate with the ET-B genotypes. The overall regression model was not significant, F 
(3, 46) = 0.81, p = .497, with the model explaining 5% of the variance overall. After 
controlling for platelet count, the ET-B genotypes did not contribute a significant amount 
of variance to the model, ∆F (2, 46) = 0.32, p = .725, ∆R2 = .01.  
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 Finally, for pain duration, fetal hemoglobin was entered as a covariate with the 
ET-B genotypes. The overall regression model was significant, F (4, 44) = 2.65, p = .046, 
with the model explaining 19% of the variance in pain duration overall. After controlling 
for fetal hemoglobin, the ET-B genotypes approached significance as a contributor of 
variance to the model, ∆F (2, 45) = 2.89, p = .066, ∆R2 = .11.  The beta coefficient 
comparing the A/G to the A/A genotype was significant as an individual predictor of pain 
duration, t (1, 47) = 2.39, p = .021. The beta coefficient comparing the G/G to the A/A 
genotype was not significant though it was in the expected direction, t (1, 47) = 1.33, p = 
.191.  Cumulatively, these results do not lend consistent support for the G allele 
conferring greater risk than the A allele, though it is noted that the largest observed effect 
for the G allele was found with pain duration. 
 Supplemental Analysis: Pre-Hydroxyurea Pain Measures. As with Study One, 
supplemental analyses were conducted to determine whether hydroxyurea may have 
altered the pain outcomes in a manner that would attenuate the effects of the ET-B 
genotypes. Biserial correlations between the ET-B genotypes and pre-hydroxyurea pain 
outcomes were used to determine if the strength and direction of associations differed 
from the original analysis (see Tables 5.6 and 5.8 for correlations and Tables 5.7 and 5.9 
for means and standard deviations). 
 For the full sample, the association between the ET-B correlation comparing the 
G/G versus the A/A genotype approached significance for medical record health care 
utilization (r = -.21, p = .080); however, it was in the opposite direction to what was 
hypothesized. A similar effect was found for medical record health care utilization in the 
subsample of children with HbSS and HbSβ0  (r = -.22, p = .135); however, it was in also 
 104 
 
in the wrong direction. There were no other notable changes in correlations for either the 
full sample or subsample. 
 Supplemental Analysis: Alternate Pain Measures. Supplemental analyses were 
also conducted to determine whether alternative pain measures would have resulted in 
more robust effects with the ET-B genotypes. Two methods were used in this analysis. 
First, dichotomous variables were created for both health care utilization outcomes and 
pain rate and compared to the ET-B genotypes. The original, untransformed variables 
were dummy coded into 0 (no pain) and 1 (at least one pain episode).  These specific 
variables were used because the continuous distributions demonstrated the most non-
normal patterns characterized by a positive skew with several values of 0. In addition, a 
previous genetic association study had dichotomized pain in this manner in a pediatric 
SCD population; thus, there was precedent for using this approach (Chaar, et al., 2006). 
Second, the health care utilization outcomes were analyzed again using only emergency 
room visits and hospitalizations, which tend to be associated with severe pain episodes, 
and this variable was analyzed both as a continuous and dichotomous variable. 
 Chi-square analysis and biserial correlations were used to examine these 
exploratory relationships (Tables 5.10 and 5.11). For the full sample, there were 
significant relationships for correlations comparing the A/G to the A/A genotype for the 
dichotomous versions of medical record health care utilization (r = .29, p = .013) and 
emergency room visits and hospitalizations (r = .27, p = .019). In addition, this same 
association approached significance with the dichotomous version of caregiver- and 
child-reported health care utilization (r = .21, p = .077) and was significant for caregiver- 
and child- reported emergency room visits and hospitalizations (r = .35, p = .002). 
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However, as with previous analyses demonstrating this effect, the correlations comparing 
the G/G and A/A genotype were not significant for these outcomes nor were they in the 
expected directions (r ranged from -.13 to -.20; p ranged from .090 to .327).  
 For the subsample of children with HbSS and HbSβ0, the correlation comparing 
the A/G to the A/A genotype approached significance for the dichotomous version of 
caregiver- and child-reported emergency room visits and hospitalizations (r = .28, p = 
.052); however, the correlation comparing the G/G and A/A genotype was not significant 
or in the expected direction (r = -.03, p = .850).  
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Table 5.1. 
Full Sample: Biserial Correlations between Endothelin B Receptor Genotypes, Covariates, and Pain Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
†p  <  .10  *p  <  .05  ***p  <  .001  ET-B = Endothelin B Receptor 
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. ET-B (G/G vs. A/A) -         
2. ET-B (A/G vs. A/A) -.62*** -        
3. Age -.01 -.04 -       
4. Gender -.06 -.01 .13 -      
5. Pain Rate -.06 .10 .01 -.02 -     
6. Pain Intensity -.01 -.03 .11 -.11 -.02 -    
7. Pain Duration -.11 .27* .03 .03 .08 .15 -   
8. Health Care Utilization  
(Caregiver and Child) 
.05 .08 .08 -.13 .53*** .24* .18 -  
9. Health Care Utilization  
(Medical Record) 
-.15 .22† .15 .07 .38** .25* .14 .67*** - 
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Table 5.2. 
Full Sample: Mean Differences in Pain Outcomes by the Endothelin B Receptor 
Genotypes  
 
 
Pain Outcome 
 
Overall 
M (SD) 
A/A  
M (SD) 
A/G  
M (SD) 
G/G  
M (SD) 
N N = 74 n = 17 n = 33 n = 24 
 
Pain Rate 
 
6.63  
(9.25) 
5.79  
(8.13) 
7.64  
(11.05) 
5.81  
(7.28) 
 
Pain Intensity 
 
7.24 
(1.68) 
7.38 
(1.28) 
7.18 
(1.63) 
7.21 
(2.04) 
 
Pain Duration 
 
2.49 
(1.86) 
1.85 
(2.11) 
3.04 
(1.91) 
2.20 
(1.42) 
 
Health Care Utilization 
(Caregiver and Child Report) 
6.36 
(9.26) 
3.85 
(6.31) 
7.15 
(8.39) 
7.04  
(11.85) 
 
Health Care Utilization  
(Medical Record) 
3.39 
(4.07) 
2.76 
(3.33) 
4.36 
(4.72) 
2.50 
(3.40) 
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Table 5.3. 
Sickle Cell Anemia and Sickle Cell Beta-0-Thalassemia Subtypes: Biserial Correlations between Endothelin B Receptor Genotypes, Covariates, 
and Pain Outcomes 
*p  <  .05  ***p  <  .001  HC = Health Care  ET-B = Endothelin B Receptor
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 
1. ET-B 
(G/G vs. A/A) 
-              
2. ET-B 
(A/G vs. A/A) 
-.63*** -             
3. Age .10 .06 -            
4. Gender -.17 .12 .18 -           
5. Alpha Thalassemia -.15 .09 -.03 .11 -          
6. Hematocrit -.02 .01 -.04 -.16 .04 -         
7. Fetal Hemoglobin -.02 -.02 -.19 .30* -.19 .58*** -        
8. White Blood Cells -.18 .21 -.14 -.02 .32* -.35* -.45** -       
9. Platelets -.17 .10 -.03 .01 -.21 .00 -.07 .01 -      
10. Pain Rate .13 -.12 .05 .05 .31* .05 .05 .01 -.08 -     
11. Pain Intensity .07 -.02 .00 -.02 -.03 .09 -.15 .03 .21 -.14 -    
12. Pain Duration -.03 .28* -.08 .04 .13 .06 -.20 .18 .08 .11 .18 -   
13. HC Utilization  
(Caregiver and Child) 
.18 -.07 .12 -.10 -.02 .13 .02 -.08 .09 .40* .22 .26† -  
14. HC Utilization  
(Medical Record) 
-.12 .17 .22 .22 .06 .04 -.02 -.11 .13 .27* .21 .29* .62*** - 
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Table 5.4. 
Sickle Cell Anemia and Sickle Cell Beta-0-Thalassemia Subtypes: Multiple Hierarchical 
Regressions for Endothelin B Receptor Genotypes Predicting Pain Outcomes 
 
 
Note. Pain rate was log-transformed to generate the final results. The original untransformed 
unstandardized beta coefficients and standard errors are presented alongside the final values. The 
untransformed values are first, followed by the log-transformed values. Values are separated by a slash. 
†p  <  .10  *p  <  .05   
   
Variable B B SE β ∆R2 Total R2 
Outcome: Pain Rate      
Covariate 
    Alpha Thalassemia 
 
.64/.04 
 
1.35/.08 
 
.08 
.01 .01 
ET-B Genotypes 
    G/G vs. A/A 
    A/G vs. A/A 
 
1.60/.16 
-.66/.10 
 
2.64/.15 
2.45/.14 
 
.20 
.14 
.02 .03 
Outcome: Pain Intensity      
Covariate 
    Platelet Count 
 
.00 
 
.00 
 
.19 
.04 .04 
ET-B Genotypes 
    G/G vs. A/A 
    A/G vs. A/A 
 
.49 
.17 
 
.64 
.59 
 
.14 
.05 
.01 .05 
Outcome: Pain Duration      
Covariate 
    Fetal Hemoglobin 
 
-.03 
 
.02 
 
-.20 
.04 .04 
ET-B Genotypes 
    G/G vs. A/A 
    A/G vs. A/A 
 
.82 
1.39* 
 
.62 
.58 
 
.24 
.42 
.11† .15 
Outcome: Health Care Utilization 
(Medical Record) 
     
Covariates 
    Age 
    Gender 
 
.25 
1.55 
 
.19 
1.17 
 
.19 
.19 
.08 .08 
ET-B Genotypes 
    G/G vs. A/A 
    A/G vs. A/A 
 
-.29 
.98 
 
1.66 
1.53 
 
-.03 
.12 
.02 .10 
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Table 5.5. 
Sickle Cell Anemia and Sickle Cell Beta-0-Thalassemia Subtypes: Mean Differences in 
Pain Outcomes by Endothelin B Receptor Genotypes  
 
 
Pain Outcome 
 
Overall 
M (SD) 
A/A  
M (SD) 
A/G  
M (SD) 
G/G  
M (SD) 
N N = 50 n = 11 n = 23 n = 16 
 
Pain Rate 
 
6.18 
(6.57) 
 
6.05 
(7.48) 
5.37 
(4.79) 
7.44  
(8.22) 
Pain Intensity 
 
7.56 
(1.60) 
 
7.36 
(1.45) 
7.52 
(1.56) 
7.72 
(1.83) 
Pain Duration 
 
2.48 
(1.63) 
 
1.56 
(1.97) 
2.96 
(1.49) 
2.42 
(1.35) 
Health Care Utilization 
(Caregiver and Child Report) 
7.29 
(9.74) 
5.27 
(7.51) 
6.52 
(7.03) 
9.78 
(13.76) 
Health Care Utilization  
(Medical Record) 
4.02 
(4.17) 
3.45 
(3.75) 
4.78 
(4.60) 
3.13 
(3.84) 
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Table 5.6. 
Supplemental Analysis for the Full Sample: Pre-Hydroxyurea Biserial Correlations 
between Endothelin B Receptor Genotypes and Pain Outcomes  
 
 
†p  <  .10  ***p  <  .001  ET-B = Endothelin B Receptor  
  
Variable 1. 2. 3. 4. 5. 6. 7. 
1. ET-B (G/G vs. A/A) -       
2. ET-B (A/G vs. A/A) -.62*** -      
3. Pain Rate -.05 .06 -     
4. Pain Intensity -.13 .00 .05 -    
5. Pain Duration -.16 .09 .01 .21† -   
6. Health Care Utilization  
(Caregiver and Child) 
-.09 .12 .49*** .44*** .19† -  
7. Health Care Utilization  
(Medical Record) 
-.21† .16 .59*** .20† .10 .38** - 
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Table 5.7. 
Supplemental Analysis for the Full Sample: Pre-Hydroxyurea Mean Differences in Pain 
Outcomes by Endothelin B Receptor Genotypes 
 
 
 
Pain Outcome 
 
Overall 
M (SD) 
A/A  
M (SD) 
A/G  
M (SD) 
G/G  
M (SD) 
N N = 72 n = 17 n = 32 n = 23 
 
Pain Rate 
 
8.78 
(13.83) 
 
8.35  
(11.68) 
9.77  
(16.61) 
7.72 
(11.25) 
Pain Intensity 
 
7.53 
(2.05) 
 
8.06 
(2.01) 
7.53 
(1.74) 
7.14 
(2.46) 
Pain Duration 
 
3.65 
(3.52) 
 
4.09 
(4.67) 
3.99 
(3.81) 
2.84 
(1.63) 
Health Care Utilization 
(Caregiver and Child Report) 
8.51 
(15.73) 
 
7.38 
(12.00) 
10.55 
(19.91) 
6.43  
(10.81) 
Health Care Utilization  
(Medical Record) 
2.20 
(2.71) 
2.44 
(3.27) 
2.66 
(2.78) 
1.36 
(2.01) 
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Table 5.8. 
Supplemental Analysis for Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Pre-
Hydroxyurea Biserial Correlations between Endothelin B Receptor Genotypes and Pain 
Outcomes 
 
 
*p  <  .05  **p  <  .01  ***p  <  .001  ET-B = Endothelin B Receptor 
  
Variable 1. 2. 3. 4. 5. 6. 7. 
1. ET-B  
(G/G vs. A/A) 
-       
2. ET-B  
(A/G vs. A/A) 
-.63*** -      
3. Pain Rate .01 .00 -     
4. Pain Intensity -.02 -.07 -.05 -    
5. Pain Duration -.11 -.09 -.14 .18 -   
6. Health Care Utilization  
(Caregiver and Child) 
-.07 .08 .46** .46** .16 -  
7. Health Care Utilization  
(Medical Record) 
-.22 .16 .60*** .12 -.02 .34* - 
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Table 5.9. 
Supplemental Analysis for Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Pre-
Hydroxyurea Mean Differences in Pain Outcomes by Endothelin B Receptor Genotypes 
 
 
Pain Outcome 
 
Overall 
M (SD) 
A/A  
M (SD) 
A/G  
M (SD) 
G/G  
M (SD) 
N N = 49 n = 11 n = 23 n = 15 
 
Pain Rate 
 
10.31 
(15.29) 
 
10.00 
(12.65) 
10.30 
(18.31) 
10.57 
(12.92) 
Pain Intensity 
 
8.03 
(1.89) 
 
8.41 
(2.35) 
7.89 
(1.56) 
7.96 
(2.11) 
Pain Duration 
 
3.73 
(3.01) 
 
5.02 
(5.40) 
3.44 
(2.05) 
3.23 
(1.41) 
Health Care Utilization 
(Caregiver and Child Report) 
11.30 
(18.38) 
10.73 
(13.94) 
12.89 
(23.29) 
9.27 
(12.57) 
Health Care Utilization  
(Medical Record) 
2.65 
(3.02) 
3.00 
(3.81) 
3.14 
(3.01) 
1.64 
(2.31) 
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Table 5.10. 
Supplemental Analysis for the Full Sample: Biserial Correlations and Chi-Square Associations for Endothelin B Receptor Genotypes 
with Alternative Pain Measures  
 
 
†p  <  .10  *p  <  .05  **p  <  .01  ***p  <  .001  ET-B = Endothelin B Receptor 
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. ET-B (G/G vs. A/A) -         
2. ET-B (A/G vs. A/A) -.62*** -        
3. Pain Rate (dichotomous)  -.08 .19 -       
4. Health Care Utilization  
(Caregiver and Child dichotomous) 
-.14 .16 76*** -      
5. Health Care Utilization 
(Medical Record dichotomous) 
.07 .10 .31** .30** -     
6. Emergency Room/Hospitalizations  
(Caregiver and Child) 
-.13 .21† .37** .40*** .75*** -    
7. Emergency Room/Hospitalizations 
(Medical Record) 
-.18 .29* .34** .52*** .36** .60*** -   
8. Emergency Room/Hospitalizations 
(Caregiver and Child dichotomous) 
-.12 .35** .51*** .52*** .60*** .72*** .64*** -  
9. Emergency Room/Hospitalizations 
(Medical Record dichotomous) 
-.20† .27* .38** .56*** .40*** .62*** .94*** .70*** - 
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Table 5.11. 
Supplemental Analysis for Sickle Cell Anemia and Beta-0-Thalassemia Subtypes: Biserial Correlations and Chi-Square Associations 
for Endothelin B Genotypes with Alternative Pain Measures 
 
 
†p  <  .10  *p  <  .05  **p  <  .01  ***p  <  .001  ET-B = Endothelin B Receptor 
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 
1. ET-B (G/G vs. A/A) -         
2. ET-B (A/G vs. A/A) .36** -        
3. Pain Rate (dichotomous)  .09 .31* -       
4. Health Care Utilization  
(Caregiver and Child dichotomous) 
-.09 .20 .83*** -      
5. Health Care Utilization 
(Medical Record dichotomous) 
-.15 .18 .31* .49*** -     
6. Emergency Room/Hospitalizations 
(Caregiver and Child) 
-.02 .10 .27† .32* .40** -    
7.  Emergency Room/Hospitalizations 
(Medical Record) 
-.11 .00 .28* .35* .50*** .80*** -   
8.  Emergency Room/Hospitalizations 
(Caregiver and Child dichotomous) 
-.12 .27† .57*** .68*** .68*** .47*** .50*** -  
9.  Emergency Room/Hospitalizations 
(Medical Record dichotomous) 
-.15 .18 .31* .49*** 1.00*** .40** .50*** .68***  
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CHAPTER 6 
DISCUSSION 
 The current project focused on two studies that had a common goal of explaining 
pain heterogeneity in pediatric SCD. The first study sought to examine an integrated, 
biopsychosocial model of pain while the second study sought to examine a novel genetic 
marker of pain in pediatric SCD. The sections below will discuss each of these aspects of 
the project separately, including limitations that are specific to each aim. A separate 
section is provided afterwards that discusses general limitations that cut across the 
studies. The document concludes with a discussion of clinical implications and future 
research directions. 
6.1 Study One: Examine an Integrated, Biopsychosocial Model of Pain in Pediatric 
SCD 
 Study One examined a biopsychosocial model of pain through three aims. The 
first two aims focused on understanding the contribution of child biological and 
psychological predictors to multiple pain features, with a focus on understanding the 
relative effect sizes of these predictors (Aim I) and determining whether these factors 
worked in an additive versus an interactive manner (Aim II). The third aim sought to 
understand the role of caregiver and family factors in relation to child psychological 
factors and multiple pain features. Consistent with the biopsychosocial model, the 
findings suggest that a combination of biological, psychological, and social factors are 
necessary for understanding pain variability in SCD.  
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 Aim I: Compare the effect sizes of biological and psychological factors in 
relation to multiple pain outcomes in pediatric SCD. Aim I focused on examining the 
relative effect sizes of biological and child psychological factors in explaining variability 
in multiple pain features.  The results suggested that both biological and psychological 
variables are important for understanding pain variability; however, the relative effect 
sizes varied according to specific pain features. The most consistent finding suggested 
that biological factors played a stronger role in explaining average pain intensity versus 
child psychological factors. In contrast, both biological and child psychological factors 
were found to be important for explaining pain rate and health care utilization. These 
results and limitations specific to Aim I are described below. 
 For pain intensity, biological factors were found to explain more variance than 
child psychological factors in the models for both the full sample and the subsample of 
patients with HbSS and HbSβ0.  Specifically, the range for R2 was .06 to .07 for 
biological variables versus .01 to .02 for child psychological variables. This finding was 
in direct contrast to hypothesis 2, which predicted that child psychological factors would 
have a moderate effect size (R2 = .12) in relation to pain intensity and which made no 
prediction for biological factors. This hypothesis was based on previous daily diary 
studies that have found significant relationships between positive and negative mood and 
pain intensity in children and adults with SCD (Gil, et al., 2003; Gil, et al., 2004).  Two 
prior cross-sectional studies were unable to find a significant relationship between coping 
strategies and pain intensity, suggesting that methodological differences may have 
accounted for the discrepancy in findings (Anie, Steptoe, Ball, Dick, & Smalling, 2002; 
Gil, et al., 1991). Specifically, child psychological factors may play a greater role in 
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immediate reporting of pain intensity that is captured in daily diaries versus average 
retrospective ratings over a period of time. It is notable that no previous studies have 
examined biological risk factors in relation to this particular pain outcome (as shown in 
Table 1.2). The current findings suggest that pain intensity, when averaged over time, 
may be an important clinical outcome for biomedical studies.  
 In contrast, for pain rate and health care utilization, both biological and child 
psychological factors were found to be important, with some models suggesting that child 
psychological factors accounted for greater variance than biological factors. For pain rate, 
the range for R2 was .11 to .16 for psychological variables versus .02 to .04 for biological 
variables (sickle cell risk group and hematocrit and fetal hemoglobin, respectively). If 
this estimate included the biological covariate (i.e., alpha thalassemia trait) from the 
subsample of children with HbSS and HbSβ0, the larger end of the range increases to .09 
for biological variables, which is somewhat more comparable to psychological factors. 
Positive mood was also found to be a significant individual predictor of pain rate and 
there was a trend for negative thinking in the full sample. Of note is that prior studies 
have not found significant associations between child psychological factors and pain rate, 
though these studies predominantly focused on coping strategies rather than mood (Anie, 
et al., 2002; Gil, et al., 1991). The present study suggests that both biological and child 
psychological factors may be relevant for this particular pain outcome. 
 For health care utilization, both caregiver and child report and medical record 
variables were considered. The results suggested a fairly large discrepancy in effect size 
between child psychological and biological factors, with R2 ranging from .10 to .23 for 
psychological factors versus .01 to .05 for biological factors. Considering additional 
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biological variables from models in the subsample (i.e., alpha thalassemia, platelet count) 
raises the effect size range to .09 to .12 for biological variables, which is somewhat more 
comparable to psychological variables. These results consistently supported hypothesis 2, 
which anticipated a moderate effect size for psychological factors (R2 = .08), and partially 
supported hypothesis 1, which anticipated a small to moderate effect size for biological 
factors in predicting health care utilization (R2 = .05). These findings are in line with 
previous research suggesting that both biological and child psychological factors play a 
role in health care utilization for pain in SCD (Anie, et al., 2002; Gil, et al., 1991). 
 Although no primary hypotheses were made for pain duration, this outcome was 
evaluated as a relevant aspect of the pain experience in pediatric SCD.  The most notable 
finding for pain duration was for the subsample of children with HbSS and HbSβ0, for 
whom biological factors approached significance as a contributor of variance (R2 = .10). 
Fetal hemoglobin also emerged as a significant predictor in this model. For psychological 
variables, the R2 ranged from .04 to .09; however, there were no notable individual 
predictors. These findings are consistent with previous work that has failed to find 
significant associations between coping strategies and pain duration in pediatric SCD 
(Anie, et al., 2002; Gil, et al., 1991). The present study replicated this finding for coping 
strategies and also failed to find an association between mood and pain duration. It is also 
notable that previous biomedical studies have not focused on pain duration (see Table 
1.2). Similar to pain intensity, this variable may be an important clinical outcome in 
biomedical studies for children with HbSS and HbSβ0. Cumulatively, these findings 
suggest that biological factors play a stronger role versus child psychological factors in 
predicting pain duration for children with SCD.  
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 In terms of limitations, there were two caveats specific to Aim I that should be 
noted. First, there were more psychological than biological predictors in the models; thus, 
there may have been greater opportunity to accumulate explained variance for 
psychological variables in the models for Aim I. The models for Aim II (described in 
greater detail below), which restricted the number of psychological variables, were 
compared to Aim I to assess this hypothesis. This comparison suggested that the effect 
size for psychological variables may have been inflated for the full sample model for pain 
duration, which had an R2 estimated at .04 for psychological variables in Aim II (versus 
R2 = .09 in the model for Aim I). Similarly, the effect size for psychological variables 
may have been inflated for the model of caregiver- and child-reported health care 
utilization with the subsample of children with HbSS and HbSβ0, which had an R2 
estimated at .11 for psychological variables in Aim II (versus R2 = .15 in the model for 
Aim I). 
 Another limitation to these findings was that several children (n = 40) were taking 
hydroxyurea at the time of the study, which may have attenuated the effects of biological 
variables. Based on the supplemental analysis that was conducted with pre-hydroxyurea 
ratings, the effect size for medical record health care utilization was likely attenuated 
(pre-hydroxyurea R2 estimate = .03 to .07 versus .01 to .05), with the pre-hydroxyurea 
results suggesting more consistent support for a small to moderate effect size for 
biological factors (i.e., sickle cell risk group and hematocrit and fetal hemoglobin), 
consistent with hypothesis 1. The effect size for pain intensity may also have been 
attenuated for biological variables (pre-hydroxyurea R2 estimate = .11 to .14 versus .06 to 
.07), though this result does not affect the interpretation above. Finally, the estimates for 
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pain rate and duration were not substantially altered and do not affect the interpretation of 
results.  
 In conclusion, the results from Aim I suggest that both biological and child 
psychological factors are important for understanding pain variability in pediatric SCD. 
In addition to replicating previous findings for pain duration and health care utilization, 
the work from Aim I also provided additional information regarding the role of biological 
risk factors in relation to average pain intensity and duration and the role of psychological 
factors in relation to pain rate. Aim II, described in the next section, was designed to 
complement these findings by determining whether biological and psychological factors 
should be viewed in an additive or interactive manner, a question that has not been 
addressed in prior studies.  
 Aim II: Explore interrelationships among biological and psychological 
factors.  The focus of Aim II was to determine whether biological and child 
psychological factors worked in an additive or interactive manner in relation to multiple 
pain features. For interaction effects, a particular focus was placed on identifying 
synergistic or buffering effects for child psychological factors and biological risk. Due to 
the small sample size and concerns about power, both statistical significance and effect 
sizes were used to determine the likelihood of an interactive effect being present in the 
sample. Given these limitations, the results should be viewed as preliminary findings that 
can inform future work. The most consistent finding was an additive effect for pain rate. 
The models also demonstrated an interaction effect for health care utilization; however, 
the results were inconsistent across models and difficult to interpret. These results and 
limitations specific to Aim II are described below. 
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 For pain rate, the results for the full sample and subsample of children with HbSS 
and HbSβ0 consistently demonstrated an additive effect, with the interaction effects 
accounting for minimal variance (less than 1%). This finding suggests that biological and 
child psychological factors may play independent roles in explaining variability in pain 
rate. This result also suggests that psychological factors may not moderate biological 
risk; thus, psychosocial interventions may be less helpful for altering pain rate if children 
are not presenting with risk factors, such as high levels of negative thinking or low levels 
of positive mood. This finding is consistent with a view of pain that considers biological 
and psychological factors as independent aspects of the pain experience (Edwards, et al., 
2005).  
 It is notable that pain rate demonstrated an additive effect whereas health care 
utilization demonstrated an interactive effect (see below), as these outcome variables 
demonstrated moderate to large correlations with one another (r = .27 to .53, Tables 4.1 
and 4.4). Although related, these variables have important distinctions that should be 
noted. Specifically, pain rate is meant to capture episodes managed both at home and via 
health care contact; thus, this variable likely captured both mild and severe episodes of 
pain. In contrast, health care utilization was more likely to capture only severe episodes 
that required medical attention. As noted in the introduction, health care utilization is also 
a complex construct that involves both pain and additional factors, such as decision 
making (Reese & Smith, 1997). These differences may partially account for the 
discrepancy in findings. 
 For health care utilization, all of the models demonstrated potential interactive 
effects, as indicated by effect sizes greater than 1% for the interaction terms (R2 range of 
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.03 to .10). Also, the subsample of children with HbSS and HbSβ0 demonstrated larger 
effect sizes for the interaction terms for health care utilization versus the full sample. The 
direction of the interaction effects was inconsistent for the health care utilization 
variables in the full sample. In addition, although the results were more consistent for the 
subsample, the findings were difficult to interpret due to characteristics of the sample, 
including the high use of hydroxyurea and its effects on hematocrit and fetal hemoglobin. 
The following paragraphs describe these issues and possible interpretations. 
 For the full sample, the results were conflicting, with the model for caregiver- and 
child-reported health care utilization suggesting an interaction in which child 
psychological factors had a stronger relationship with health care utilization for children 
with low- versus high-risk subtypes and the model for medical record health care 
utilization suggesting the opposite. The reason for this discrepancy is unclear as these 
models were essentially identical in terms of variables. These outcome variables were 
also highly correlated, suggesting that they are largely capturing the same construct.  
 An evaluation of the components of the health care utilization variables (see Table 
3.4) did suggest a discrepancy in the number of doctor visits and calls that comprise these 
variables, with the caregiver- and child-reported variable comprising more of these types 
of visits compared to the medical record variable. Thus, although related, the caregiver- 
and child-reported variable may have represented broader utilization whereas the medical 
record variable may have been more representative of utilization required for severe 
episodes. It is possible that psychological factors played a larger role in influencing 
broader forms of utilization for the low- versus high-risk subtypes of SCD  (as shown by 
the caregiver and child report variable) whereas these factors played a larger role in 
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influencing utilization requiring hospitalization or emergency department visits in the 
high- versus low-risk subtypes (as shown by the medical record variable). Although 
possible, these explanations must also be tempered by the possibility of Type I error. 
 For the subsample, the models suggested that psychological factors played a 
stronger role in children who had lower hematocrit (both models) and fetal hemoglobin 
levels (caregiver and child report). The original hypotheses regarding biological risk 
factors assumed that higher hematocrit and lower fetal hemoglobin would be indicative of 
higher biological risk, a finding that is based on the largest epidemiological study of 
children and adults with SCD (Platt, et al., 1991). However, characteristics of the sample, 
including the high rate of hydroxyurea treatment and the focus on a pediatric population, 
make these findings somewhat difficult to interpret. In order to evaluate these findings, 
the following approach was undertaken: (a) examine the main effects of hematocrit and 
fetal hemoglobin, (b) determine how hydroxyurea may have impacted the findings, and 
(c) present information from the literature regarding possible alternative explanations. 
 First, the main effects of hematocrit and fetal hemoglobin were examined. 
Hematocrit demonstrated a positive association with health care utilization for both 
models, suggesting that higher hematocrit was associated with higher health care 
utilization overall. Fetal hemoglobin demonstrated less consistent relationships, with the 
caregiver- and child-reported model suggesting a negative association and the medical 
record model suggesting a positive association with health care utilization. These results 
are inconsistent for fetal hemoglobin, but suggest that higher hematocrit may have 
represented higher biological risk in the sample. 
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 The effects of hydroxyurea were also examined using information on hydroxyurea 
status and therapeutic response (see Table 6.1). The majority of children with HbSS and 
HbSβ0 were taking hydroxyurea at the time of the study (77% of the subsample), which is 
known to increase both hematocrit and fetal hemoglobin (Rosse, Narla, Petz, & 
Steinberg, 2000). Several of these children had also established a partial or good 
therapeutic response (n = 28, 54% of the subsample), meaning that they had 
demonstrated a positive lab response that included higher hematocrit and fetal 
hemoglobin levels. Notably, examination of mean differences in health care utilization 
based on hydroxyurea status suggested that those taking hydroxyurea had similar levels 
of hematocrit and higher levels of fetal hemoglobin, but had higher rates of health care 
utilization versus those not taking hydroxyurea. For those with a partial or good response, 
children had similar levels of hematocrit and higher levels of fetal hemoglobin, but either 
demonstrated similar (caregiver and child report variable) or higher rates of health care 
utilization (medical record variable) versus those with no response.  
 These findings are not surprising as children taking hydroxyurea are likely to have 
the highest rate of health care utilization of the sample; however, the results suggest that 
hydroxyurea may have increased hematocrit and fetal hemoglobin in these children 
without necessarily lowering their rate of health care utilization relative to other children 
in the sample. Thus, these findings support higher hematocrit and fetal hemoglobin as 
being indicative of higher biological risk in the present sample of children, as the result of 
these children being a higher risk group of patients in terms of pain, but also having 
artificially high levels of hematocrit and fetal hemoglobin due to hydroxyurea.  
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 Finally, studies specific to pediatric populations were reexamined to determine 
alternative explanations for the findings. There has been inconsistency in the literature 
regarding the role of hematocrit in pediatric populations, with some studies supporting 
the original epidemiological investigation by Platt and colleagues (1991) and others 
suggesting that lower hematocrit is indicative of higher biological risk. A daily diary 
study with a small sample of children with SCD by Dampier and colleagues (2004) was 
able to replicate the findings of the original epidemiological study, with higher 
hematocrit associated with higher pain rate. In contrast, in a large epidemiological study 
specific to children with SCD, lower hemoglobin, of which hematocrit is a derivative, 
was associated with greater disease severity as measured by a combination of adverse 
events, including pain rate (Miller, et al., 2000). Hargrave and colleagues (2003) also 
found a similar relationship between lower hematocrit and higher rates of health care 
utilization for pain in smaller sample of children with SCD. This literature supports the 
possibility of lower hematocrit being associated with higher biological risk. 
 Collectively, these findings do not provide a clear interpretation of the findings, 
particularly for fetal hemoglobin. However, based on the evaluation of main effects in the 
final models and the results evaluating group differences in hematocrit by hydroxyurea 
treatment status, there is more support for higher hematocrit being indicative of higher 
biological risk for this specific sample of children. Thus, in these models, child 
psychological factors may have had a stronger relationship with health care utilization for 
those with lower rather than higher biological risk in the subsample. 
 Considering these findings together, it is notable that three of the four models 
suggested that child psychological factors had a stronger relationship with health care 
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utilization for children with lower rather than higher biological risk. There are multiple 
interpretations for this finding. First, the results may suggest that psychological factors 
are more likely to alter pain in children with low to moderate risk, including children with 
low risk subtypes and those with milder disease risk in the high risk subtypes; however, 
there may be a population of children with high biological risk who require health care 
utilization for pain and whose pain is less affected by psychological factors. Although 
this finding was not in the hypothesized direction, it is still consistent with modern 
theoretical models of pain, which suggest that pain is the result of interplay between 
biological and psychological risk factors (Edwards, Campbell, Jamison, & Wiech, 2009; 
Keefe & France, 1999; Melzack, 1999). Alternatively, this finding may suggest that 
psychological factors play a greater role in decision-making for health care use in 
children with low to moderate biological risk versus those with higher biological risk. 
The latter interpretation would be supported by theoretical models specific to health care 
utilization, which suggest that the decision to use health care in SCD is the product of 
multiple factors, including disease status and pain-related distress (Reese & Smith, 1997). 
 In terms of additional pain outcomes, interaction effects were not examined for 
pain intensity due to small effect sizes for psychological variables. For pain duration, 
results for the full sample suggested an interaction effect in which psychological factors 
had a stronger effect for children with low- versus high-risk subtypes. This finding was 
not replicated for the subsample of children with HbSS and HbSβ0, suggesting that 
psychological factors differentiated pain duration between high- and low-risk subtypes, 
but did not differentiate pain duration within the high risk group. This finding is 
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consistent with the above findings and suggests that child psychological factors may alter 
the effects of lower, but not higher biological risk for pain duration.     
 As with Aim I, a primary limitation of Aim II was the high use of hydroxyurea in 
the subsample, which interfered with establishing a firm interpretation of how the 
biological risk factors were impacting health care utilization in the subsample of children 
with HbSS and HbSβ0. In addition, due to the small sample size and limited power, it was 
difficult to establish which interaction terms were most important to investigate in the 
models. Specifically, only one model (medical record health care utilization for the 
subsample) demonstrated a clear interaction term (hematocrit and positive mood) that 
was driving the result.  
 The unstandardized beta coefficients were provided in the results to better 
describe the potential interaction effects. The results for positive mood, in particular, 
suggested that interactions accounting for the lowest effect sizes may have been less 
clinically meaningful. For example, for the full sample model with caregiver- and child-
reported health care utilization, the difference in slope for positive mood between 
children with high- versus low-risk subtypes was about half of one health care visit. In 
contrast, for the subsample model with medical record health care utilization, which had 
the largest effect size for interaction terms, the difference in slope for positive mood 
between children with higher versus lower hematocrit was close to three health care 
visits. Thus, while a larger sample would be beneficial for replicating these results and 
establishing statistical significance, the clinical meaningfulness of the effects is also 
important. Future studies may consider powering results to detect a small to moderate 
effect size. 
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 In conclusion, the results from Aim II provided support for both additive and 
interaction relationships between biological and child psychological risk factors 
depending on specific pain features. Pain rate demonstrated a consistent additive model 
whereas health care utilization demonstrated a consistent pattern of interactive models. 
Pain duration also demonstrated a potential interactive model with the full sample. 
Across interactive models, there was more support for child psychological factors playing 
a stronger role in children with lower as opposed to higher biological risk. 
 Aim III: Examine relationships between child psychological variables, 
caregiver psychological variables, family functioning, and pain outcomes. The focus 
of Aim III was to examine the impact of caregiver and family variables on child 
psychological variables and multiple pain features. A particular emphasis was placed on 
establishing possible mediators that could inform future family-based intervention efforts. 
The results supported the potential of mediation analysis to uncover important family 
processes that impact pain outcomes in children with SCD. The results also provided 
additional information that may have utility for family-based work, even in the absence 
of mediation analysis. These results and limitations specific to Aim III are described 
below. 
  In terms of possible mediation, the findings suggested that child negative 
thinking could be a mediator of the relationship between caregiver passive coping and 
negative mood with health care utilization. In other words, caregiver passive coping and 
negative mood may result in higher negative thinking in the child that ultimately leads to 
greater health care utilization. Unfortunately, the results suggested that a large sample 
would be needed to conduct a powered mediation analysis to detect this relationship, with 
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an estimated 148 to 196 children and caregivers needed (Fritz & Mackinnon, 2007). 
Although mediation analysis would be ideal for informing family-based intervention 
work, the remaining findings from the study along with previous literature provide strong 
evidence for the importance of including caregivers in pain management interventions for 
children. 
 First, the correlation analysis replicated the finding that child coping tends to 
mirror caregiver coping. This was particularly apparent for trends that supported 
relationships between child negative thinking and caregiver passive coping as well as 
child and caregiver positive mood. This finding is consistent with several previous 
studies suggesting the importance of caregivers in modeling and teaching coping 
strategies for pain (Brown, et al., 1993; Gil, et al., 1991; Kliewer & Lewis, 1995; Lutz, et 
al., 2004). Second, findings from the present study suggest that caregiver psychological 
factors may have both indirect (i.e., mediated) and direct effects on pain outcomes. 
Specifically, the findings from the supplemental analysis suggested that higher caregiver 
negative mood may be directly associated with pain duration and that higher caregiver 
active and passive coping may be directly associated with health care utilization. Health 
care utilization, in particular, is a construct that is likely to be influenced by both the 
child’s health status and caregiver decision-making in SCD (Reese & Smith, 1997). 
These findings suggest the importance of caregivers in both the development of coping 
strategies for pain and in the direct management of pain. 
 One unusual finding from the correlation analysis was that caregiver active and 
passive coping were positively associated. This finding suggests that caregivers may use 
a combination of both active and passive coping strategies, rather than relying on one or 
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the other. Of note is that higher caregiver active coping was related to higher health care 
utilization. Children similarly showed a positive association between coping attempts and 
negative thinking; however, a higher level of coping attempts was related to lower health 
care utilization. Of note is that caregiver active coping was weakly and negatively related 
to child coping attempts, suggesting that children were less likely to mirror this type of 
caregiver coping. One possible interpretation for these findings is that children may be 
less likely to engage in coping attempts if their caregiver is actively addressing their pain 
and vice versa; however, in order to experience a reduction in health care utilization, the 
child may need to be directly engaged in active coping attempts. This interpretation 
would be consistent with a previous study on family processes in SCD, which suggested 
that certain family processes may encourage dependence on the caregiver rather than 
independent coping in the child (Kliewer & Lewis, 1995). 
 Finally, family functioning was not related to any of the pain outcomes, though it 
was related to child negative thinking as well as caregiver passive coping, positive mood, 
and negative mood. This variable may not have established relationships with pain 
outcomes because it is a more distal variable compared to child or caregiver 
psychological factors. This variable also seemed to overlap with several of the caregiver 
variables and was completed by caregivers, suggesting that it may simply represent 
another manifestation of caregiver psychological status in the present study. One 
limitation of Aim III was the absence of child report of family functioning. Due to the 
concerns about the time required to complete the study measures, children were not asked 
to complete a parallel version of the family functioning scale. The scale used was also 
meant to capture broad aspects of family functioning rather than specific family 
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dynamics. Future studies may consider adding the child’s perspective on family 
functioning or using the full version of the scale to obtain a more nuanced picture of 
family functioning. 
 In conclusion, the results from the study provided preliminary support for the use 
of mediation analysis in future studies; however, a large sample size would be needed to 
conduct an appropriately powered analysis. Although this work would be informative, the 
results from the study replicate previous research findings and suggest the importance of 
caregiver factors in the development of coping strategies for pain. In addition, the results 
suggest that specific caregiver psychological factors, such as negative mood and passive 
coping, may directly impact pain outcomes in SCD. Thus, even in the absence of 
additional mediation analyses, it is clear that caregivers contribute to the variability 
observed in pain outcomes for children with SCD. 
6.2 Study Two: Examine a Novel Genetic Marker of Pain in Pediatric SCD 
 The focus of Study Two was to establish a novel genetic marker of pain in 
pediatric SCD by specifically focusing on the ET-B SNP (rs5351). Multiple analyses 
were completed in an attempt to replicate a preliminary study suggesting that the G allele 
of this SNP was related to greater pain severity versus the A allele in children with SCD; 
however, none of the models replicated this relationship. A summary of the findings as 
well as limitations and alternative explanations for the results are described below.  
 The primary model examined was for health care utilization, with exploratory 
analyses completed for additional pain outcomes. The models for medical record health 
care utilization and pain duration in the full sample were able to demonstrate that the AG 
genotype group had higher utilization for pain than the AA genotype group; however, the 
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models were unable to demonstrate a similar relationship between the GG and AA group, 
which is necessary for replicating the codominant model described in the preliminary 
results. The latter relationship, in particular, should have demonstrated the greatest 
difference in health care utilization, as children with the GG genotype would be assumed 
to have the greatest risk for pain. In contrast, some models suggested that the AA 
genotype group had higher health care utilization than the GG genotype group. The 
model for pain duration in the subsample was able to demonstrate these relationships in 
the expected directions; however, the difference between the GG and AA genotypes in 
the regression models was smaller than that of the AG and AA genotypes, which again 
runs counter to the preliminary data.  
 Additional analyses were completed with pre-hydroxyurea pain outcomes, in 
order to determine whether hydroxyurea may have attenuated the relationship between 
the ET-B genotypes and pain outcomes. These models were generally similar to the 
original results, with several models demonstrating a difference in pain severity between 
the AG and AA genotypes; however, the difference between the GG and AA genotypes 
was either weaker or not in the expected direction. In addition, alternative pain outcomes 
were used to determine whether the genotypes distinguished between categories of 
children (i.e., children with or without any health care utilization for pain) or to determine 
whether the genotypes distinguished between children with and without more severe pain 
requiring hospitalization or emergency room visits. These analyses resulted in similar 
findings to the primary models.  
 The means between groups were also evaluated to help interpret the analyses. One 
unusual finding that appeared was an underdominant effect, in which the heterozygote 
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AG group demonstrated greater pain severity versus both the AA and GG genotypes. For 
example, this relationship can be seen in the models for medical record health care 
utilization and pain duration in both the full sample and subsample of children. This 
effect is unusual and has not been demonstrated in previous studies with the ET-B SNP 
(Dong, et al., 2004; Iemitsu, et al., 2006); thus, it seems unlikely to be meaningful in the 
present study.  
 There are a few alternative explanations for these findings that should be noted. 
The first possibility is that there is an effect with the ET-B SNP that could not be detected 
in the sample, either due to the relatively small sample size or due to other factors related 
to the sample (i.e., the use of hydroxyurea). The hypothesized pattern of mean differences 
can be observed in the subsample for the caregiver- and child-reported health care 
utilization variable and for the pre-hydroxyurea pain rate variable; however, this pattern 
is absent from all other pain outcomes, despite the large number of models examined. 
Thus, it seems unlikely that this relationship would be consistently detected in a larger 
sample. The use of hydroxyurea may have also altered the natural course of pain in the 
sample and may have attenuated pain in children who would have otherwise 
demonstrated the highest pain ratings. On the other hand, the results from Aim II in Study 
One suggested that children taking hydroxyurea continued to demonstrate higher rates of 
health care utilization than other children. In addition, the pre-hydroxyurea analyses were 
not significantly different from the primary models. 
 Another explanation relates to the finding of an underdominant effect for some of 
the pain outcomes. An underdominant effect is an unusual finding that may be indicative 
of issues with admixture in the sample. Admixture can occur when different populations 
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interbreed, resulting in different haplotypes or combinations of genes that are inherited 
(Deng, 2001). Admixture has been discussed as a potential issue for genetic studies in 
SCD. Specifically, the sickle cell beta globin mutation that results SCD developed 
independently in different ethnic groups in Africa and other parts of the world. Although 
these ethnic groups all carry the same mutation that causes SCD, they may inherit other 
genes that alter disease course. For example, a haplotype from Senegal has been 
associated with fewer pain episodes and hospitalizations than other groups. In the United 
States, it is widely recognized that African-American patients with SCD likely represent 
a combination of ethnic groups, resulting in admixture (Steinberg, 2005). Although many 
genetic studies assume that ethnic groups will be randomly distributed into different 
genotype groups for the SNP under consideration, this issue remains a possibility (Deng, 
2001). 
 A third explanation is that the relationship in the preliminary data was the result 
of SCD genotype effects rather than the ET-B SNP. In the preliminary data, it is notable 
that the GG genotype group was only comprised of children with HbSS, a high-risk 
subtype, whereas the other groups were comprised of a combination of SCD genotypes. 
Thus, it is possible that the preliminary data was demonstrating a SCD subtype effect 
rather than an effect of the ET-B SNP. Finally, the association in the preliminary data 
may have been found due to chance and was simply not replicated in a larger sample. 
Replication has been a widely discussed issue for genetic association studies (Cardon & 
Bell, 2001). 
 In conclusion, the present study was unable to replicate preliminary data 
suggesting that the G allele of the ET-B SNP is associated with greater pain severity 
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versus the A allele. Although several explanations were provided to explain the results, 
the most parsimonious and likely explanations are that the relationship in the preliminary 
date was the result of SCD genotype differences or was due to chance, though admixture 
could have been a possible confounding factor in the study.  
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Table 6.1. 
Supplemental Analysis: Mean Differences in Hematocrit, Fetal Hemoglobin, and Health 
Care Utilization based on Hydroxyurea Status and Therapeutic Response
Treatment Status Hematocrit 
 
Fetal 
Hemoglobin 
Health Care 
Utilization 
(Caregiver 
and Child) 
Health Care 
Utilization 
(Medical 
Record) 
Hydroxyurea Status 
    Taking hydroxyurea 
    Not taking hydroxyurea 
M (SD) 
25.11 (3.89) 
25.94 (2.93) 
M (SD) 
14.30 (9.90) 
9.73 (8.44) 
M (SD) 
8.55 (10.51) 
2.25 (1.62) 
M (SD) 
4.73 (4.38) 
1.67 (1.37) 
Therapeutic Response  
    Good or partial response 
    No response 
 
25.71 (3.39) 
23.85 (4.65) 
 
17.83 (9.29) 
7.24 (7.03) 
 
8.44 (11.93) 
8.77 (7.11) 
 
5.11 (4.94) 
3.93 (2.90) 
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CHAPTER 7 
GENERAL LIMITATIONS 
 The results noted above should be considered in the context of general limitations 
that cut across multiple aims of the study. The following issues are described below: (a) 
the use of a cross-sectional approach and causality, (b) pain measurement, 3) sample size 
and power, and (c) generalizability. 
 The use of a cross-sectional approach is a key limitation of the study that limits 
inferences that can be made regarding causality. This limitation is particularly important 
when considering the results from Study One. Specifically, previous authors have noted 
the possibility that child and caregiver psychological factors are a consequence rather 
than a predictor of severe pain (Gil, et al., 2003; Gil, et al., 2004). There has been 
minimal research examining temporal precedence in SCD; however, one prior study by 
Gil and colleagues (2003) suggested that pain intensity, in particular, may be a precipitant 
rather than a consequence of mood changes in adolescents with SCD. Similar research 
has yet to be conducted with other pain features; thus, it is unclear whether these findings 
would apply to pain rate or health care utilization, which demonstrated the most 
consistent effects with child and caregiver psychological factors. 
In the present study, one method for identifying temporal precedence would be to 
examine whether biological and psychological risk factors are associated. Sickle cell 
genotype, in particular, can be assumed to temporally precede the development of coping 
strategies or mood changes in pediatric SCD. As shown in demonstrated a moderate 
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association with SCD genotype, such that children with high-risk subtypes reported 
higher levels of negative thinking versus those with low-risk subtypes. Thus, this 
particular child psychological factor may have represented a consequence rather than a 
predictor of pain severity. Of note is that the most consistent child psychological 
predictor of pain in the study, positive mood, did not demonstrate a significant 
relationship with SCD genotype. Although it is not possible to confirm causality between 
pain and psychosocial factors in the present study, modern conceptualizations of pain 
suggest that these factors are likely to have bidirectional relationships with one another 
(Keefe & France, 1999). Future work in this area, particularly with the use of daily 
diaries, may provide more specific information about temporal precedence and causality. 
 A second limitation of the study is the manner in which pain was measured. In the 
present study, child and caregiver reports and medical records were used to measure pain 
features. For child and caregiver reports, one particularly important limitation is recall 
bias (Shiffman, Stone, & Hufford, 2008). Children and their caregivers generally 
demonstrated only moderate associations in their reports of pain. For this reason, child 
and caregiver ratings were averaged to avoid over- or underestimation of pain. Despite 
this approach, it is likely that the retrospective reports contained measurement error due 
to inaccuracies in recalling health information over the previous year. This issue likely 
posed an even greater issue for the pre-hydroxyurea analysis, which required varying 
amounts of time for caregiver recall in order to establish pre-hydroxyurea pain ratings. 
 In addition, previous research has suggested that the psychological state of an 
individual can bias retrospective reporting of events, including for children who are asked 
to recall pain (Van Den Brink, Bandell-Hoekstra, & Huijer Abu-Saad, 2001) Thus, it is 
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possible that child and caregiver psychological factors were associated with pain 
outcomes because of reporting bias rather than their direct influence on pain. It is notable 
that the largest effect size for child psychological factors was observed for health care 
utilization as measured by the medical record. While this measure is partially based on 
caregiver reports in the medical chart, it is also based on documented health care visits, 
which would not be influenced by reporting bias. It is also notable that psychological 
factors were not consistently related to all pain outcomes. Thus, if reporting bias did exist 
based on psychological status, the bias did not affect pain outcomes equally.  
 The use of medical record reviews also has specific limitations that should be 
noted, including potential issues with missing information and difficulty interpreting 
information in the chart (Gearing, Mian, Barber, & Ickowicz, 2006). The medical chart 
measure of health care utilization was strongly related to the child and caregiver ratings; 
however, the medical record variable resulted in similar or lower ratings of health care 
utilization versus child and caregiver reports, despite representing twice as much time. 
This finding suggests that the medical record may have been missing information or that 
children and caregivers were overestimating their utilization. 
 An alternative approach to measuring pain is the use of prospective daily diaries, 
which are considered the gold standard for measuring pain. Although the use of pain 
diaries has clear advantages over retrospective recall, it is unclear how much time would 
have been needed in order to obtain a representative assessment of pain in the present 
study. For example, many children with SCD go for weeks or months without pain and 
then may have periods of more frequent pain. In addition, given the sample size desired 
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and resources available for the study, the collection of daily diaries over a long period of 
time would not have been feasible.  
 Another key limitation to the study was the relatively small sample size and issues 
related to power. Post hoc power analysis suggested that a sample of 76 participants was 
powered to detect an effect size equivalent to an R2 of .10. The sample of 52 children 
with HbSS and HbSβ0 was powered to detect an R2 of .14. Issues related to power were 
most problematic for detecting statistical significance for the biological predictors and the 
interaction terms. These issues were anticipated in the study and the use of effect size 
estimates and unstandardized beta coefficients was used to determine the meaningfulness 
of the results. For the interaction results, this analysis suggested that models with small 
effect sizes may have been less likely to be clinically meaningful versus models with 
moderate effect sizes. Thus, future studies may consider powering studies to detect an 
effect size between small and moderate, which is more likely to be clinically meaningful. 
Power may also have been an issue for the genetic analysis; however, even with a larger 
sample, the direction of findings would not have been in the expected direction. 
 A final consideration is the generalizability of the study. The study sample had 
very good representations of SCD genotypes, with the frequencies closely approximating 
those found in the overall population of patients with SCD (i.e., approximately 63% 
HbSS, 25% HbSC, and 11% for both HbSβ+ and HbSβ0); however, other characteristics 
of the sample may be less likely to generalize to other children.  First, all of the children 
in the study must have been receiving care through a comprehensive sickle cell center. 
Thus, children with milder disease presentations who chose not to receive comprehensive 
sickle cell care or those who were unable to attend routine hematological visits are less 
 143 
 
likely to be represented in the study. Second, over half of the children in the study were 
taking hydroxyurea at the time of the study and these children varied in their treatment 
status in terms of whether they had established a therapeutic response. Although the use 
of hydroxyurea has increased in recent years, the prevalence of this treatment in the 
overall population of children with SCD is unclear. It is likely that children taking 
hydroxyurea were overrepresented in the present study due to our recruitment approach. 
Specifically, children taking hydroxyurea typically attend routine clinic visits every two 
months, as opposed to every 6-12 months for routine health maintenance visits; thus, 
children taking hydroxyurea had more frequent clinic visits that made recruitment more 
likely. As noted previously, the use of hydroxyurea primarily affected the effect size and 
interpretation of hematocrit and fetal hemoglobin. The interaction results, in particular, 
are likely to be specific to the present sample. 
 In conclusion, the results of this study should be considered with the above 
limitations in mind. In particular, alternative explanations related to causality and 
reporting bias should be considered when evaluating the findings. In addition, the extent 
to which the findings are relevant for other pediatric SCD populations should be 
considered, both in terms of clinical meaningfulness and generalizability. The final 
sections below discuss clinical implications and future research directions, considering 
the interpretations from the discussion and limitations sections. 
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CHAPTER 8 
CLINICAL IMPLICATIONS 
 The findings from the present study provide information that may have utility for 
future intervention planning. In particular, the findings have implications for structuring 
interventions, incorporating caregivers, and using biomarkers in prevention efforts. These 
areas are discussed below. 
 As noted in the introduction, the biopsychosocial model has the potential to 
inform integrated biomedical and behavioral treatments for pain. The present study 
provides information that may be helpful in determining who is most likely to benefit 
from these interventions and the changes in pain outcomes that can be expected. 
Specifically, the results from Study One suggest that a combined medical and behavioral 
approach to treatment may be most beneficial in altering pain rate and health care 
utilization. For pain rate, the preliminary results consistently found an additive model, 
suggesting that an integrated approach is most likely to alter pain for children presenting 
with psychological risk factors for this particular outcome. For health care utilization, the 
results found an interactive model and suggested that children with low to moderate 
disease risk may be most likely to experience a reduction in health care utilization using 
an integrated approach. In contrast, children with very high disease risk may not 
experience changes in health care utilization with the addition of a behavioral component. 
 It is important to note that these findings are specific to pain rather than functional
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outcomes. Many children, particularly those at high disease risk, may still benefit from a 
combined medical and behavioral approach to pain that targets functional consequences, 
including depression, anxiety, and poor quality of life (Barakat, et al., 2007; Burlew, et 
al., 2000; Chen, et al., 2004). The results from the present study were designed to 
complement this work by also highlighting the changes that may occur using an 
integrated approach to address both pain and functional outcomes. 
 The present study also has implications for incorporating caregivers into 
treatment. The present findings, along with previous work, suggest that caregivers may 
play both indirect and direct roles in modifying their children’s pain (Logan, et al., 2002; 
Lutz, et al., 2004; Mitchell, et al., 2007). Unfortunately, existing work has not 
demonstrated clear efficacy for incorporating family members into treatment (Anie & 
Green, 2012; Chen, et al., 2004); however, it is clear that caregivers are important to 
consider in intervention planning. In addition to demonstrating efficacy, future 
intervention work may need to evaluate the effects of incorporating caregivers into a 
largely child-focused intervention (an indirect approach), which is what the majority of 
previous intervention work has done, versus targeting the behaviors and parenting 
practices of caregivers themselves (a direct approach). Also, future intervention work 
may consider a more preventative approach to pain that provides psychoeducation and 
training in behavioral strategies to caregivers for children early in life.  
 Finally, both Study One and Two incorporated biomarkers in an attempt to predict 
pain outcomes, with Study One focused on laboratory markers and Study Two focused on 
a novel genetic marker. The use of biomarkers remains the only method for trying to 
predict future disease risk early in life in SCD; however, both studies highlighted 
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important limitations to this work, including small effect sizes for biomarkers and 
difficulty with replication. In addition, as seen in the present study, the use of 
hydroxyurea may limit the ability of existing laboratory markers to predict future pain. 
Although previous studies have excluded children receiving hydroxyurea, this approach 
may become less feasible over time as this treatment approach becomes more common. 
These limitations suggest that this work may not be immediately impactful in terms of 
prevention efforts and that it will take time to develop models that have clinical utility for 
predicting pain. At the same time, the identification of biomarkers continues to have 
utility for developing novel treatment approaches; thus, even in the absence of a 
prevention framework, this work continues to be an important aspect of developing new 
medical approaches for pain. 
 This section has highlighted some of the clinical implications that may arise from 
pursuing an integrated, interdisciplinary approach to pain in pediatric SCD. The 
following section describes future research directions that would be helpful in continuing 
to inform this work. 
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CHAPTER 9 
FUTURE RESEARCH DIRECTIONS 
 The present study poses several important research directions for studying pain in 
pediatric SCD. This section highlights three broad issues that would particularly benefit 
from additional research: (a) understanding developmental aspects of SCD, (b) improving 
pain measures in SCD, and (c) refining the biopsychosocial model. 
 The current study emphasized work on children in order to inform a discussion of 
early prevention and intervention efforts for pain and to provide information that could 
specifically address issues pertinent to a pediatric population.  One finding that emerged 
from this project is the importance of understanding how biopsychosocial constructs 
operate in children and how these factors change over the course of development. In 
terms of biomedical factors, it is notable that there is inconsistency regarding the role of 
hematocrit for pain in children with SCD, particularly since the original epidemiological 
findings for hematocrit occurred over 20 years ago (Platt, et al., 1991). Given this 
inconsistency, it would be helpful for researchers to reevaluate the role of hematocrit in 
existing data sets of children with SCD or for new research to be conducted evaluating 
the impact of hematocrit over the course of childhood in SCD. This work would be 
particularly useful in determining whether hematocrit is a meaningful marker to use for 
predicting pain severity in children with SCD.  
 In terms of psychosocial factors, one unique component of childhood is that 
children change over time from being predominantly reliant on caregivers to becoming
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independent in managing their pain. Previous developmental research has been helpful in 
identifying important developmental periods for the stabilization of coping strategies in 
children with SCD (Gil, et al., 1993). It would be helpful to have similar research 
conducted with caregivers to better understand their role in the management of pain over 
time, including during infancy and early childhood. This work may help to inform 
caregiver- and family-based interventions for pain in pediatric SCD (Anie & Green, 
2012; Chen, et al., 2004). 
 The present study also highlighted limitations to current measurement tools in 
pediatric SCD and the need for additional research in this area. In particular, future 
research would be helpful in identifying how different measurement approaches influence 
results for pain in SCD. For example, it would be helpful to know the concordance of 
daily diaries and retrospective ratings of pain in SCD and whether the concordance varies 
by child age. Similarly, it would be useful to know if a patient’s psychological state is 
likely to impact their ratings. Finally, it would be beneficial to know how different 
definitions of pain in SCD influence results, such as the impact of including home-based 
episodes of pain versus focusing on just health care utilization. Although inferences can 
be made for some of these research questions, having more specific information on the 
strengths and weaknesses for these tools in SCD could help to inform the strategies that 
researchers use for measuring pain and how limitations of specific measures impact the 
findings. 
  Finally, previous researchers have noted the importance of refining the 
biopsychosocial model for pain conditions (Keefe & France, 1999). A particular strength 
of the current study was the examination of how biological and psychosocial factors work 
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together to impact pain in pediatric SCD, which had not been the focus of any prior 
studies. The current study also incorporated multiple psychosocial factors (i.e., child 
coping and mood) in the same model. Future work is needed both to replicate the findings 
from this study and to further clarify how biological and psychosocial factors work 
together in this condition. In particular, research on temporal precedence would be 
beneficial. In addition, it would be helpful to identify other psychosocial constructs that 
may be relevant for this condition based on literature in other pain populations. For 
example, mood has received widespread attention in the pain literature, but has been less 
widely studied in SCD, despite being one of the more consistent psychological predictors 
in the present project (Keefe, et al., 2005). Additional psychological constructs, such as 
self-efficacy, may benefit from additional attention in studies of pain in SCD (Turk & 
Okifuji, 2002). 
 To conclude, the present project integrated biomedical and psychosocial 
approaches to understand pain heterogeneity in pediatric SCD. The project contributed 
several new findings to the literature on pediatric SCD, but also highlighted the 
complexity of this condition. In particular, the project suggests that pain in pediatric SCD 
may be best viewed in terms of both a developmental and biopsychosocial perspective. In 
addition, pain in this condition must be viewed in the context of changes in medical care, 
such as the increasing use of hydroxyurea, which may fundamentally alter relationships 
between biological risk and pain outcomes. It is clear that future work on pain in pediatric 
SCD will require interdisciplinary approaches that are able to refine existing models and 
fit novel predictors in the context of a complicated and changing disease. 
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